The storylines故事线
Click a development’s source links to open the original article.点击进展下方的来源链接可打开原文。
DiaSys acquisitionDiaSys收购
2 · 2024-01-02 → 2024-04-26
▾
Mindray completes acquisition of DiaSys to strengthen IVD internationalization迈瑞完成DiaSys收购，强化IVD国际化
2024-01-02Mindray completed acquisition of DiaSys (European liquid biochemistry reagent pioneer) at end of 2023, a key step for IVD full internationalization.迈瑞医疗于2023年底完成对欧洲液体生化试剂之父德赛诊断的收购，这是推动IVD全面国际化的关键一步。
2024-04-26FY2023: Mindray completed acquisition of 75% equity of German IVD brand DiaSys to strengthen local supply chain platform.2023年迈瑞医疗完成对德国知名IVD品牌DiaSys 75%股权的收购，以加强本地化供应链平台建设。
2024 major product launches2024年重磅产品发布
14 · 2024-01-02 → 2026-03-10
▾
Mindray plans and launches multiple major products including endoscopy, ultrasound, and cardiac markers迈瑞计划并发布内窥镜、超声、心脏标志物等多款重磅产品
2024-01-02Mindray plans to launch major products in 2024 including 3D+4K+fluorescence rigid endoscopy system, ultrasonic scalpel and energy platform, cavity吻合器 (anastomat), high-sensitivity troponin and NT-proBNP cardiac markers, and ultra-high-end whole-body ultrasound.迈瑞医疗计划在2024年发布重磅产品，包括3D+4K+荧光硬镜系统、超声刀及能量平台、腔镜吻合器、高敏肌钙蛋白及NT-proBNP心肌标志物试剂、超高端全身应用超声等。
2024-04-13At CMEF, Mindray launched 30+ products and solutions covering emergency, OR, ICU, lab, ultrasound, and unveiled Mindray Digital Intelligence Lab and Mindray Smart Imaging total solution.在CMEF上，迈瑞医疗推出30多款覆盖急诊、手术室、重症、检验、超声等科室的产品及解决方案，并发布迈瑞数智实验室及迈瑞智慧影像整体解决方案。
2024-04-26Q1 2024 R&D spending RMB 1.03 billion, 10.99% of revenue; new products launched globally: CL-2600i chemiluminescence analyzer, BS-1000M biochemistry analyzer, M680 automated biochemistry-immune line, Resona/Nuewa I9 elite ultrasound, A3/A1 anesthesia system, 4K 3D electronic thoracolaparoscopic system.2024年第一季度研发投入10.3亿元，占营收10.99%；面向全球推出CL-2600i化学发光分析仪、BS-1000M生化分析仪、M680全自动生化免疫流水线、Resona/Nuewa I9精英版超声、A3/A1麻醉系统、4K三维电子胸腹腔内窥镜系统等新产品。
2024-05-11At the performance briefing, Mindray guided that in 2024, minimally invasive surgery consumables (ultrasonic scalpel,腔镜吻合器) are about to ramp up; chemiluminescence will add ~20 new core projects; fully self-developed TLA line MT-8000 new installations may exceed historical total; ultra-premium ultrasound Resona A20 will accelerate global high-end hospital penetration.在业绩说明会上，迈瑞医疗表示2024年微创外科耗材（超声刀、腔镜吻合器）即将放量；化学发光预计新增约20个全新核心项目；全自研TLA流水线MT-8000新增装机量有望超过历史存量；超高端超声Resona A20将加速全球高端医院突破。
2024-07-30Mindray completed product lineup for thoracoabdominal minimally invasive surgery, including 4K+fluorescence and 4K+3D rigid endoscopy systems, electrosurgical knife, ultrasonic knife, energy platform, and intelligent stapler with >98% staple formation rate.迈瑞医疗完成胸腹腔微创外科手术产品布局，包括4K+荧光和4K+3D胸腹腔硬镜系统、电刀、超声刀、能量平台及成钉良率超98%的智能腔镜吻合器。
2024-08-26At the 18th NCLM in Hangzhou, Mindray launched nearly 50 new reagents and an AI-upgraded Mindray Smart Lab total laboratory solution.在杭州第十八次NCLM上，迈瑞医疗发布了近50项新试剂，以及AI赋能升级的迈瑞智检全实验室解决方案。
2024-10-29Mindray launched new products in Q3 2024: TE Air e5M wireless handheld ultrasound, MX7 obstetrics advanced edition, BeneHeart E/L/H semi-automatic AEDs, BeneHeart R900/R700/R300 ECG machines, NH9 high-flow respiratory humidifier, SV700/SV900 ventilators.迈瑞医疗2024年第三季度推出新产品：TE Air e5M无线掌上超声、MX7妇产高阶版、BeneHeart E/L/H系列半自动体外除颤器、BeneHeart R900/R700/R300全数字心电图机、NH9高流量呼吸湿化治疗仪、SV700/SV900呼吸机。
2024-12-19Mindray guided that in 2025, key new products will include the ultra-high-end obstetric ultrasound Neuwa A20, the全身应用 ultra-high-end ultrasound Resona A20 (launched late 2023), 4K+3D+fluorescence rigid endoscopy system,腔镜吻合器, and over 15 new chemiluminescence reagent items.迈瑞医疗指引2025年重磅新品包括妇产超高端超声Neuwa A20、全身超高端超声Resona A20、4K+3D+荧光硬镜系统、腔镜吻合器及15项以上全新化学发光试剂项目。
2025-04-02Mindray completed product layout for thoracoabdominal minimally invasive surgery, with 4K+fluorescence and 4K+3D rigid endoscopy systems, electrosurgical knife, ultrasonic knife, energy platform, and endoscopic stapler launched; minimally invasive surgery business grew over 45% in first three quarters of 2024.迈瑞医疗完成胸腹腔微创外科手术产品布局，推出4K+荧光和4K+3D胸腹腔硬镜系统、电刀、超声刀、能量平台、腔镜吻合器等；2024年前三季度微创外科业务增长超过45%。
2025-04-29Mindray announced it will release a new-generation high-speed chemiluminescence and biochemical analyzer, plus a fully automated流水线 (automated line), by end of 2025; it plans to add at least 15 chemiluminescence assays annually for three years.迈瑞医疗宣布将于2025年底发布全新一代高速化学发光和生化分析仪及全自动化流水线；未来三年每年新增至少15项化学发光项目。
2025-05-19Mindray plans to launch a new generation of high-speed chemiluminescence and biochemical analyzers, plus fully automated流水线 (assembly lines), by end of 2025; aims to add at least 15 chemiluminescence items annually over three years.迈瑞医疗计划2025年底推出全新一代高速化学发光和生化分析仪及全自动化流水线；未来三年每年新增至少15项化学发光项目。
2025-07-09Mindray expects to complete the last hormone panel in chemiluminescence in 2025, catching up with imported brands in five core routine panels; MT 8000 full-lab automation line overseas installations to ramp up in 2025.迈瑞医疗预计2025年补齐最后的激素套餐，在化学发光五大核心常规套餐上追赶进口品牌；MT 8000全实验室智能化流水线海外装机将逐步放量。
2025-09-03Mindray launched 8 new chemiluminescence reagent products in H1 2025, bringing total to 88; accelerated raw material substitution via HyTest Bio to improve performance and control costs.2025年上半年，迈瑞医疗新推出8个化学发光试剂产品，上市产品总数量增至88个；借助海肽生物加速免疫试剂原材料替换以提升性能、控制成本。
2026-03-10Mindray disclosed that in Q3 2025 it launched 3 chemiluminescence immunoassay reagents (high-sensitivity cardiac troponin T, D-dimer, free testosterone) and several new products in生命信息与支持, including RuiZhi perioperative decision support system, 4K 3D全域 fluorescence imaging platform, SV50 ventilator, and surgical staplers.迈瑞医疗披露2025年第三季度推出了高敏心肌肌钙蛋白T、D-二聚体、游离睾酮等3项化学发光免疫试剂，以及瑞智围术期决策辅助系统、4K三维全域荧光智能影像平台、SV50呼吸机、腔镜切割吻合器等生命信息与支持领域新产品。
Magnifice (HK) share reductionsMagnifice（HK）减持
1 · 2024-01-17
▾
Magnifice (HK) and related platforms reduce holdings, cashing out over 1.6 billion yuanMagnifice（HK）等平台减持，套现超16亿元
2024-01-17Magnifice (HK) and other platforms linked to co-founder Xu Hang reduced holdings by several million shares in Q2 2023, cumulatively cashing out over 1.6 billion yuan.2023年第二季度，徐航关联的持股平台大幅减持数百万股，累计套现超16亿元。
Magnifice (HK) share pledges and releasesMagnifice（HK）股份质押与解押
26 · 2024-01-22 → 2026-06-24
▾
Controlling shareholder Magnifice (HK) repeatedly pledges and releases shares控股股东Magnifice（HK）反复质押和解押股份
2024-01-22Shareholder Magnifice (HK) pledged 3.565 million shares (12.01% of its holding) as of Jan 22, 2024; additional pledge of 4.1 million shares (0.34% of total) to Ping An Bank Shenzhen branch.截至2024年1月22日，股东Magnifice(HK)累计质押3565万股（占其所持股份12.01%）；另向平安银行深圳分行质押410万股（占总股本0.34%）。
2024-03-15Major shareholder Magnifice (HK) pledged 3.2 million shares (0.26% of total) to Ping An Bank Shenzhen Branch.控股股东Magnifice(HK)向平安银行深圳分行质押320万股，占总股本0.26%。
2024-03-25Major shareholder Magnifice (HK) pledged 7.85 million shares (0.65% of total) to China Merchants Bank New York Branch.控股股东Magnifice(HK)向招商银行纽约分行质押785万股，占总股本0.65%。
2024-03-29Major shareholder Magnifice (HK) released a pledge of 7.5 million shares (0.62% of total) to China Merchants Bank New York Branch; remaining pledged shares 39.2 million (13.20% of its holding, 3.23% of total).控股股东Magnifice(HK)解除向招商银行纽约分行质押的750万股（占总股本0.62%）；剩余质押3920万股（占其持股13.20%，占总股本3.23%）。
2024-06-12Controlling shareholder Magnifice (HK) Limited pledged 3.55 million shares (0.29% of total shares) to Chiyu Banking Corporation for debt repayment; cumulative pledged shares reached 14.40% of its holdings.控股股东Magnifice（HK）Limited质押355万股（占总股本0.29%）给集友银行，用于偿还债务；累计质押股份占其持股的14.40%。
2024-06-24Controlling shareholder Magnifice (HK) Limited released a pledge on 5.6 million shares (0.46% of total shares) to Nanyang Commercial Bank; cumulative pledged shares reduced to 12.51% of its holdings.控股股东Magnifice（HK）Limited解除质押560万股（占总股本0.46%）给南洋商业银行；累计质押股份降至其持股的12.51%。
2024-08-01Mindray's controlling shareholder Magnifice (HK) Limited released a pledge of 1.35 million shares (0.11% of total shares) to Ping An Bank Shenzhen Branch on July 31, 2024.迈瑞医疗控股股东Magnifice（HK）Limited于2024年7月31日解除了向平安银行深圳分行质押的135万股（占总股本0.11%）。
2024-09-25Mindray controlling shareholder Magnifice (HK) Limited released a pledge of 4.8M shares (0.40% of total) to Ping An Bank Shenzhen Branch.迈瑞医疗控股股东Magnifice（HK）解除质押480万股（占总股本0.40%），质权人为平安银行深圳分行。
2024-11-06Controlling shareholder Magnifice (HK) Limited pledged 25.35 million shares (2.09% of total share capital) to Ping An Bank, Shanghai Pudong Development Bank, and China Merchants Bank for debt repayment, and simultaneously released 9.05 million shares from pledge.控股股东Magnifice(HK) Limited向平安银行、浦发银行、招商银行质押2535万股（占总股本2.09%）用于偿还债务，同时解除质押905万股。
2024-11-06Mindray's controlling shareholder Magnifice (HK) Limited pledged an additional 5.20 million shares (0.43% of total share capital) to China Merchants Bank (Wing Lung) for debt repayment, and released 14.15 million shares from pledge (6.80 million + 7.35 million). Cumulative pledged shares reached 44.17 million (3.64% of total share capital).控股股东Magnifice(HK) Limited向招商永隆银行新增质押520万股（占总股本0.43%）用于偿还债务，并解除质押1415万股（680万+735万）。累计质押4417万股（占总股本3.64%）。
2024-11-14Mindray confirmed that the share pledge by controlling shareholder Magnifice (HK) is a shareholder personal act, not a corporate action, and disclosed that the Trump administration's impact is being monitored.迈瑞医疗确认控股股东Magnifice(HK)的股权质押为股东个人行为，非公司行为，并表示正在关注特朗普政府的影响。
2025-01-16Shareholder Magnifice (HK) Limited pledged 4.7 million shares (0.39% of total) to Ping An Bank Shenzhen Branch.股东Magnifice(HK)Limited向平安银行深圳分行质押470万股，占总股本0.39%。
2025-02-17Controlling shareholder Magnifice (HK) Limited released a pledge on 900,000 shares of Mindray; after release, 44.77 million shares remained pledged, with market value of approximately 11.588 billion yuan based on closing price of 258.84 yuan.控股股东Magnifice (HK) Limited解除质押迈瑞医疗90万股；解除后仍有4477万股处于质押状态，按收盘价258.84元计算市值约115.88亿元。
2025-03-12Mindray's controlling shareholder Magnifice (HK) Limited released a pledge of 10.1 million shares, representing 3.40% of its holdings and 0.83% of the company's total shares.迈瑞医疗控股股东Magnifice（HK）Limited解除质押1010万股，占其所持股份的3.40%，占公司总股本的0.83%。
2025-04-23Mindray disclosed that controlling shareholder Magnifice (HK) has pledged 11.68% of its shares, down from a historical high of 33.65%, with no margin call risk currently.迈瑞医疗披露控股股东Magnifice（HK）质押股份占其持股比例11.68%，较历史高位33.65%大幅下降，目前无平仓风险。
2025-05-30Mindray's controlling shareholder Magnifice (HK) released a pledge of 4.3 million shares and newly pledged 9.95 million shares; cumulative pledged shares reached 40.32 million (3.33% of total share capital).迈瑞医疗控股股东Magnifice(HK)解除质押430万股并新增质押995万股；累计质押4032万股（占总股本3.33%）。
2025-06-06Controlling shareholder Magnifice (HK) Limited released a pledge on 625,000 shares (0.52% of total) and newly pledged 7.1 million shares (0.59% of total); cumulative pledged shares reached 41.17 million, or 3.4% of total shares.控股股东Magnifice (HK) Limited解除质押62.5万股（占总股本0.52%），新增质押710万股（占总股本0.59%）；累计质押股份达4117万股，占总股本3.4%。
2025-08-01Controlling shareholder Magnifice (HK) Limited released 5.82 million pledged shares, reducing its cumulative pledged shares to 35.35 million shares (11.90% of its holdings).控股股东Magnifice（HK）Limited解除质押582万股，累计质押股份降至3535万股（占其持股11.90%）。
2025-10-14Mindray's controlling shareholder Magnifice (HK) Limited pledged 4.4 million shares (1.48% of its holdings, 0.36% of total shares) to Industrial Bank Co., Ltd. Hong Kong Branch.迈瑞医疗控股股东Magnifice (HK) Limited将其持有的440万股股份（占其所持股份1.48%，占总股本0.36%）质押给兴业银行股份有限公司香港分行。
2025-10-21Mindray's controlling shareholder Magnifice (HK) Limited pledged an additional 5.8 million shares (1.95% of its holdings) to Shanghai Pudong Development Bank Shenzhen Branch, and released a previous pledge of 4.85 million shares.迈瑞医疗控股股东Magnifice (HK) Limited新增质押580万股（占其所持股份1.95%）给上海浦东发展银行深圳分行，并解除此前质押的485万股。
2026-03-10Controlling shareholder Magnifice (HK) pledged 8 million shares (2.69% of its holdings, 0.66% of total shares) to Ping An Bank Shenzhen Branch and Jiyou Bank; cumulative pledged shares reached 44.1 million shares (14.85% of its holdings).控股股东Magnifice（HK）质押800万股（占其所持股份2.69%，占总股本0.66%）给平安银行深圳分行和集友银行；累计质押股份达4410万股（占其所持股份14.85%）。
2026-04-03Controlling shareholder Magnifice (HK) Limited pledged 3.6 million shares (1.21% of its holdings) to China Merchants Bank New York Branch as a supplemental pledge on April 1, 2026.控股股东Magnifice（HK） Limited于2026年4月1日将其所持360万股（占其持股1.21%）质押给招商银行纽约分行，用途为补充质押。
2026-04-22Controlling shareholder Magnifice (HK) Limited pledged additional shares to Industrial Bank Hong Kong Branch on April 21, 2026, as a supplemental pledge.控股股东Magnifice（HK） Limited于2026年4月21日将部分股份质押给兴业银行香港分行，用途为补充质押。
2026-05-22Mindray's controlling shareholder Magnifice (HK) Limited pledged 14.5 million shares (1.20% of total share capital) on 2026-05-21.迈瑞医疗控股股东Magnifice（HK）Limited于5月21日质押1450万股，占公司总股本1.20%。
2026-05-29Mindray's controlling shareholder Magnifice (HK) Limited released a pledge on 13.55 million shares (1.12% of total share capital).迈瑞医疗控股股东Magnifice（HK）Limited解除质押1355万股，占公司总股本1.12%。
2026-06-24Mindray's controlling shareholder Magnifice (HK) Limited pledged 6.4 million shares (0.53% of total) to Nanyang Commercial Bank and招商永隆银行 for debt repayment and other purposes.迈瑞医疗控股股东Magnifice（HK）Limited向南洋商业银行及招商永隆银行质押640万股（占总股本0.53%），部分用于偿还债务。
Trademark and IP filings商标与知识产权申请
16 · 2024-01-26 → 2026-06-06
▾
Mindray files new trademarks and registers software copyrights迈瑞申请新商标并登记软件著作权
2024-01-26Mindray filed a new trademark application '瑞凝' (Rui Ning) in January 2024, bringing total registered trademarks to 717 with 62 pending.迈瑞医疗于2024年1月新提交“瑞凝”商标注册申请，目前共持有注册商标717件，另有62件尚在申请中。
2024-04-25Mindray registered new software copyright for 'Mindray BeneHeart CS Series Automated External Defibrillator Software V2.0'.迈瑞医疗新注册《迈瑞BeneHeart CS系列自动体外除颤器软件V2.0》软件著作权。
2024-05-10Mindray registered new software copyright 'Mindray L Series AED Product Software V1.0'.迈瑞医疗新注册《迈瑞L系列AED产品软件V1.0》软件著作权。
2024-05-26Mindray registered new software copyright 'Mindray WATO Anesthesia Machine Software V2.0'.迈瑞医疗新注册《迈瑞WATO麻醉机软件V2.0》软件著作权。
2024-07-19Mindray registered new software copyright 'Mindray Large Monitor Product Fully Automated Test Production Line Operation Software V1.0'.迈瑞医疗新注册《迈瑞大监护产品全自动化测试生产线操作软件V1.0》软件著作权。
2024-09-05Mindray registered new software copyright 'Mindray Fully Automated Chemiluminescence Instrument Quality Control Monitoring Software V1.0'.迈瑞医疗新注册《迈瑞全自动化学发光仪器质控监控软件V1.0》软件著作权。
2024-12-26Mindray newly registered 4 software copyrights, including Mindray AED Quality Management Platform V1.0, Mindray Lab Automation Line Health Software V1.0, Mindray IVD Consumable Monitoring Software V1.0, and Mindray BeneVision V Series System Software V1.0.迈瑞医疗新注册4项软件著作权，包括《迈瑞自动体外除颤器产品质量管理平台V1.0》、《迈瑞实验室自动化流水线健康度软件V1.0》等。
2025-05-31Mindray registered a new software copyright for 'Mindray EV Series Surgical Smoke Evacuation System Software V1.0'.迈瑞医疗新注册《迈瑞EV系列手术烟雾处理系统软件V1.0》软件著作权。
2025-07-10Mindray filed a new trademark application for 'FR-HCG'.迈瑞医疗新提交“FR-HCG”商标注册申请。
2025-07-16Mindray registered a new software copyright for 'Mindray TV Series MRI Ventilator System Software V1.0'.迈瑞医疗新注册《迈瑞TV系列MRI呼吸机系统软件V1.0》软件著作权。
2025-08-27Registered new software copyright for 'SV30 Series Ventilator System Software V1.0'; total 4 software copyrights registered in 2025, down 50% YoY.新注册《SV30系列呼吸机系统软件V1.0》软件著作权；2025年共注册4个软件著作权，同比减少50%。
2026-02-26Mindray registered a new software copyright for the NB600 series ventilator system software V1.0.迈瑞医疗新注册了《迈瑞NB600系列呼吸机系统软件V1.0》项目的软件著作权。
2026-03-03Mindray registered a new software copyright for 'Mindray RuiZhiLian PLUS IoT Platform V1.0'; total software copyrights registered in 2026 YTD reached 2, up 100% YoY.迈瑞医疗新注册《迈瑞瑞智联PLUS物联平台V1.0》软件著作权；2026年以来累计注册软件著作权2个，较去年同期增加100%。
2026-05-10Mindray registered new software copyright 'Mindray Digital Operations Management Software V1.0'; total 3 software copyrights registered YTD, up 200% YoY.迈瑞医疗新注册《迈瑞数智运营管理软件V1.0》软件著作权；今年以来共注册3个，较去年同期增加200%。
2026-05-28Mindray registered new software copyright 'Mindray Cardiopulmonary Resuscitation Machine Series Product Software V1.0'; total 4 software copyrights registered YTD, up 100% YoY.迈瑞医疗新注册《迈瑞心肺复苏机系列产品软件V1.0》软件著作权；今年以来共注册4个，较去年同期增加100%。
2026-06-06Mindray registered a new software copyright 'Mindray Intelligent Knowledge Base Software V1.0', with 5 new software copyrights in 2026, up 150% YoY.迈瑞医疗新注册《迈瑞智能知识库软件V1.0》软件著作权，2026年以来新注册软件著作权5个，较去年同期增加150%。
Huite Medical (惠泰医疗) acquisition惠泰医疗收购
12 · 2024-01-28 → 2025-11-12
▾
Mindray acquires control of Huite Medical to enter cardiovascular device sector迈瑞收购惠泰医疗控制权，进入心血管器械领域
2024-01-28Mindray board approved acquisition of 21.12% stake in Shenzhen Huite Medical (688617.SH) for about 6.652 billion yuan via subsidiary Shenmaikong, plus 0.12% GP interest in Zhuhai Tongsheng, resulting in 24.61% total ownership and control change to Li Xiting and Xu Hang.迈瑞医疗董事会批准通过子公司深迈控以约66.52亿元收购惠泰医疗21.12%股份，并受让珠海彤昇0.12%普通合伙权益，合计持有24.61%股份，实控人变更为李西廷和徐航。
2024-01-28Mindray enters cardiovascular device sector via Huite Medical acquisition, which specializes in electrophysiology, coronary access, and peripheral vascular intervention products.迈瑞医疗通过收购惠泰医疗进入心血管器械领域，惠泰医疗主营电生理、冠脉通路及外周血管介入产品。
2024-01-28Huite Medical's actual controller Cheng Zhenghui irrevocably waives voting rights on 10% of shares after receiving full payment.惠泰医疗实际控制人成正辉承诺在收到全部股份转让价款后永久且不可撤销地放弃所持10%股份的表决权。
2024-01-28This is the first 'A-share acquires A-share' control transfer case on the STAR Market (科创板).这是科创板首单“A收A”实现控制权转让的案例。
2024-01-28Mindray's cash balance as of end-Sept 2023 was 19.667 billion yuan; the 6.652 billion acquisition is less than one-third of that, posing no significant financial pressure.截至2023年9月末，迈瑞医疗货币资金余额196.67亿元，此次66.52亿元收购不及账面资金的三分之一，不构成较大压力。
2024-02-01Mindray announced it would acquire control of Hangzhou Huide Medical (惠泰医疗, a STAR-listed cardiovascular device firm) for 6.65 billion yuan via its subsidiary Shenzhen Mindray Technology Holding (深迈控), through a share transfer and voting rights waiver, marking its first domestic M&A and entry into the cardiovascular high-value consumables sector.迈瑞医疗宣布通过子公司深迈控以66.5亿元收购科创板上市公司惠泰医疗控制权，采用协议转让加表决权放弃方式，这是其首次国内并购并切入心血管高值耗材领域。
2024-02-21China's State Administration for Market Regulation (SAMR) published a public notice period for Mindray's acquisition of Huide Medical equity, indicating antitrust review is underway.国家市场监督管理总局公示迈瑞医疗收购惠泰医疗股权案，进入反垄断审查公示期。
2024-04-15Mindray's wholly-owned subsidiary Shenzhen Mindray Technology Holding completed the acquisition of 19.72% of HuiTai Medical (19.72% of total shares) for RMB 6.652 billion; after the deal, Mindray controls 24.61% of HuiTai, and Li Xiting and Xu Hang become actual controllers.迈瑞医疗全资子公司深迈控完成收购惠泰医疗19.72%股份（总股本），交易对价66.52亿元；交易后迈瑞控制惠泰医疗24.61%股份，李西廷、徐航成为实际控制人。
2024-09-10Mindray completed acquisition of control of Huitai Medical (688617.SH) for 6.652B yuan for 21.12% stake via subsidiary Shenmaikong, marking the first 'A-control-A' on STAR Market, entering cardiovascular high-value consumables.迈瑞医疗通过子公司深迈控以66.52亿元收购惠泰医疗21.12%股份获得控制权，系科创板首单“A控A”，切入心血管高值耗材赛道。
2024-12-31Mindray confirmed that its Q3 2024 financial report has consolidated Huite Medical (惠泰医疗) into its financial statements.迈瑞医疗确认其2024年第三季度报告已将惠泰医疗纳入合并财务报表。
2025-05-28Mindray disclosed that post-acquisition of Huite Medical (control stake), the electrophysiology division was established in 2024; the 3D atrial fibrillation PFA and RFA systems and supporting consumables received NMPA approval and launched on schedule.迈瑞医疗披露收购惠泰医疗后，2024年成立电生理事业部；三维房颤PFA、RFA系统及配套耗材已获NMPA批准并如期上市。
2025-11-12Mindray stated that the significant increase of 3,371 new dealers in 2024 was due to the consolidation of HuiTai Medical into its financial statements.迈瑞医疗表示2024年新增经销商3371家，幅度比历年高出一倍，原因是惠泰医疗纳入报表。
Middle East partnerships中东合作伙伴关系
4 · 2024-02-02 → 2025-05-01
▾
Mindray signs strategic agreements with Egyptian, Saudi, and other Middle East healthcare groups迈瑞与埃及、沙特等中东医疗集团签署战略协议
2024-02-02At Arab Health 2024 in Dubai, Mindray signed strategic cooperation agreements with Egypt's largest private hospital group Cleopatra Hospitals Group and Saudi Arabia's Dallah Hospital, and inaugurated the first Mindray standardized laboratory in Saudi Arabia.在迪拜阿拉伯国际医疗设备展上，迈瑞医疗与埃及最大私立医院集团Cleopatra Hospitals Group及沙特Dallah Hospital签署战略合作协议，并在沙特揭牌首家迈瑞规范化实验室。
2024-12-02Mindray signed a strategic cooperation memorandum with Saudi Arabia's National Unified Procurement Company (NUPCO) for deeper future medical collaboration, during a visit by a Saudi delegation led by the Minister of Health.迈瑞医疗与沙特国家统一采购公司（NUPCO）签署战略合作备忘录，约定未来进行更深入的医疗合作，沙特卫生部长率团访问。
2025-02-12Mindray signed a strategic cooperation memorandum with Saudi Arabia's National Unified Procurement Company (NUPCO) to deepen medical collaboration, supporting Saudi Vision 2030 healthcare transformation.迈瑞医疗与沙特国家统一采购公司（NUPCO）签署战略合作备忘录，深化医疗合作，支持沙特2030愿景医疗转型。
2025-05-01Mindray won an order from Saudi Arabia's new private high-end health center Sukoon IEC for its Ruizhilian (Mindray Intelligent Connectivity) solution, beating two international giants in monitors and ventilators.迈瑞医疗凭借瑞智联解决方案拿下沙特阿拉伯新建私立高端康养中心Sukoon IEC的监护仪和呼吸机订单，超越两家国际巨头。
Other corporate & operational其他公司及运营
15 · 2024-02-18 → 2026-06-25
▾
Mindray applied for credit line, established new ultrasound unit, refiled Hong Kong IPO, and denied forced inventory stocking.迈瑞申请授信额度、成立新超声部门、重新提交香港IPO申请，并否认强制压货。
2024-02-18Mindray issued a 'Quality Return Dual Improvement' action plan, setting a target to rank among the global top 20 medical device companies by 2025, and committing to continued high dividends and shareholder returns.迈瑞医疗发布“质量回报双提升”行动方案，提出2025年跻身全球前二十医疗器械榜单的目标，并承诺持续高分红和股东回报。
2024-02-26Philips Commercial Displays provided Mindray's Nanjing training base with Feijing SMD fine-pitch LED displays to upgrade digital training infrastructure for medical professionals.飞利浦商显为迈瑞医疗南京培训基地提供飞晶SMD小间距LED显示屏，升级医疗从业者数字化培训设施。
2024-05-19At the 2023 annual general meeting, chairman Li Xiting stated that Mindray's key strategy is to integrate AI into its three major businesses (monitoring, blood cell, ultrasound) and to target global top 10.在2023年度股东大会上，董事长李西廷表示迈瑞医疗的重要战略是推进三大业务与AI技术相结合，并向全球前十发起冲击。
2024-08-29Mindray's 2024 half-year report noted that the MT8000 full-lab intelligent流水线 (automated line) surpassed 100 installations nationwide within one year of launch, over 90% in tertiary hospitals.迈瑞医疗2024半年报指出，MT8000全实验室智能化流水线上市一周年全国装机已突破100条，超过90%为三级医院。
2024-11-06Mindray's board secretary Li Wenmei stated that the company aims to become one of the top 20 global medical device companies by 2025, and to challenge the top 10. Strategic directions include full digital transformation of equipment business and continuous expansion of consumables layout, with resources tilted toward IVD, minimally invasive surgery, and cardiovascular seed businesses.董秘李文楣表示，迈瑞医疗目标2025年进入全球医疗器械前二十，并向全球前十发起冲击。战略方向为设备业务全面数智化转型和持续扩大耗材业务布局，资源向IVD、微创外科、心血管等种子业务倾斜。
2025-02-15Mindray registered a new software copyright for 'Mindray SV700/SV900 Series Ventilator System Software V1.0'.迈瑞医疗新注册《迈瑞SV700/SV900系列呼吸机系统软件V1.0》软件著作权。
2025-05-19Mindray's board secretary Li Wenmei stated at the SZSE Global Investor Conference that the company will continue active M&A both domestically and internationally; domestic M&A focuses on cross-sector new business (e.g., 2024 acquisition of control of Huite Medical for RMB 6.65bn).迈瑞医疗董秘李文楣在深交所全球投资者大会上表示，公司将继续积极进行境内外并购；国内并购侧重跨赛道新业务（如2024年以66.5亿元收购惠泰医疗控制权）。
2025-08-07Board approved applying for a comprehensive credit line of up to RMB 1 billion from China Export-Import Bank Shenzhen Branch, valid until August 31, 2026.董事会批准向中国进出口银行深圳分行申请不超过10亿元人民币的综合授信额度，有效期至2026年8月31日。
2025-11-06Mindray stated that Q3 2025 financial expense volatility was mainly due to foreign exchange gains/losses.迈瑞医疗表示2025年第三季度财务费用波动主要因为汇兑损益。
2025-12-04Mindray partnered with Excellence Commercial Property & Facilities Management Group for property management services at its Nanjing base (20.76万 sqm, largest R&D/production center in E China) and Hangzhou base (core minimally invasive surgery instruments site).迈瑞医疗与卓越商企服务集团合作，为其南京基地（20.76万平方米，华东最大研发生产中心）和杭州基地（微创外科手术器械核心产区）提供物业管理服务。
2026-04-29Mindray's Q1 2026 R&D investment reached RMB 889 million, accounting for 10.64% of revenue. New products launched included multiple IVD reagent kits and devices, and new Life Information & Support equipment.迈瑞医疗2026年一季度研发投入达8.89亿元，占营收10.64%。推出了多个体外诊断试剂盒和设备，以及生命信息与支持领域的新设备。
2026-05-28Mindray disclosed that its MT 8000流水线 (MT 8000 automated line) received over 360 new domestic orders and installed nearly 270 units in 2025; in 2026Q1, over 140 new orders and over 80 installations.迈瑞医疗披露MT 8000流水线2025年国内新增订单超360套、装机近270套；2026年一季度新增订单超140套、装机超80套。
2026-06-02Mindray's MT 8000 TLA line cumulative installations reached nearly 600 units; Q1 2026 domestic orders exceeded 140 sets, with March setting a monthly record of over 60 lines.迈瑞医疗MT 8000全实验室智能化流水线累计装机近600条；2026年一季度国内新增订单超140套，3月单月装机突破60条，刷新国产高端TLA流水线单月装机纪录。
2026-06-04Mindray-supported international multicenter clinical study LIGHTNING on novel cardiac biomarker Long-T ITC for NSTEMI risk stratification was launched at OCC 2026.由迈瑞医疗支持的国际多中心临床研究LIGHTNING在OCC 2026上启动，聚焦新型心肌标志物Long-T ITC用于非ST段抬高型心肌梗死患者风险分层。
2026-06-25Mindray refiled its Hong Kong IPO application on May 11 after the previous filing lapsed on May 10, advancing its Hong Kong listing plan.迈瑞医疗于5月10日港股招股书失效后，次日（5月11日）重新递表，推进香港上市计划。
Greenland Group cooperation与绿地集团合作
1 · 2024-02-19
▾
Mindray partners with Greenland Group to export AEDs and serve Belt and Road countries迈瑞与绿地集团合作出口AED并服务一带一路国家
2024-02-19Mindray signed a cooperation agreement with Greenland Group (绿地集团) to jointly export medical devices (starting with AEDs) to Belt and Road countries, serve Shanghai and Yangtze River Delta emergency rescue systems, and participate in centralized procurement distribution and public hospital SPD projects.迈瑞医疗与绿地集团签约，合作以自动体外除颤仪为切入点向“一带一路”国家出口医疗器械，服务上海及长三角应急救援体系，并参与集采配送和公立医院SPD项目。
US tariff and regulatory updates美国关税与监管动态
6 · 2024-03-01 → 2025-06-05
▾
Mindray updates on US tariff exemptions, tariff impacts, and EU IPI probe迈瑞更新美国关税豁免、关税影响及欧盟IPI调查
2024-03-01Mindray stated that its products sold to the US are partially exempt from tariffs, and the additional tariffs have not affected its North American sales; 2022 North American revenue was 2.461 billion yuan, up over 30% YoY.迈瑞表示，销往美国的部分产品已豁免关税，加征关税未影响北美销售；2022年北美营收24.61亿元，同比增长超30%。
2024-04-16Mindray responds to EU investigation into Chinese medical device procurement: it has no single contract in Europe above EUR 5 million threshold, so the IPI probe does not affect its European sales.迈瑞医疗回应欧盟拟对中国医疗器械采购启动调查：公司在欧洲没有任何单笔合同超过500万欧元门槛，因此IPI调查不影响其欧洲销售。
2024-07-25Mindray stated that the Biden administration's tariff increase does not affect its business; North America accounted for 7.45% of 2023 revenue.迈瑞医疗表示拜登政府加征关税不涉及公司业务；2023年北美地区收入占比7.45%。
2025-04-03Mindray stated that US sales revenue accounts for about 6% of total revenue; products sold in the US in 2025 are not affected by the latest tariff rounds due to advance stockpiling; US business compound growth rate was 10% from 2018-2023, and gross margin in the US exceeds 70%.迈瑞医疗表示美国销售收入占总收入约6%；因提前备货，2025年在美销售产品不受本轮关税影响；2018-2023年美国业务复合增速10%，美国业务毛利率超过70%。
2025-04-23Mindray confirmed that China's retaliatory tariffs on US imports will have a one-time impact on 2025 profit margins; the company is pursuing raw material substitution to secure supply.迈瑞医疗确认中国对美反制关税将对2025年利润率造成一次性影响；公司正通过原材料替代确保供应安全。
2025-06-05Mindray stated that EU's International Procurement Instrument (IPI) restricting Chinese firms from public tenders over EUR 5 million will not affect it, as it has no single contract above that threshold in the EU; it has localized production in 13 countries including a German IVD factory, and may expand European localization.迈瑞表示，欧盟限制中国企业参与超过500万欧元公共招标的国际采购工具（IPI）不会对其产生影响，因其在欧盟无单个合同超过该门槛；公司在包括德国IVD工厂在内的13个国家拥有本地化生产能力，并可能扩大欧洲本地化布局。
Supplier relationships供应商关系
5 · 2024-03-06 → 2026-06-08
▾
Mindray's supply chain relationships with Aweite, Jiangsu Leili, Dongni Electronics, and HyTest迈瑞与Aweite、江苏雷利、东尼电子、HyTest等供应商的关系
2024-03-06Aweite (873693) disclosed it supplies Mindray with structural parts for blood oxygen analyzers and syringe pumps; it set up a Shenzhen factory in 2020 to better serve Mindray.阿为特(873693)披露向迈瑞供应血氧分析仪结构件、注射泵结构件；2020年在深圳设厂以更好服务迈瑞。
2024-07-03Jiangsu Leili disclosed a strategic partnership with Mindray to jointly promote localization of core medical device components.江苏雷利披露与迈瑞医疗建立战略合作关系，共同推进医疗器械核心零部件国产化。
2024-11-22Dongni Electronics (603595) disclosed that Mindray is one of its major customers.东尼电子（603595）披露迈瑞医疗为其主要客户之一。
2026-05-28Mindray confirmed that its IVD reagent raw material subsidiary HyTest Ltd. supplied raw materials for 12 chemiluminescence reagent products launched in 2025.迈瑞医疗确认其IVD试剂原料子公司海肽生物为2025年上线的12项化学发光试剂产品提供原料。
2026-06-08Mindray held its annual Core Supply Partner Conference in Wuhan R&D base, with over 200 global suppliers; Suzhou Yaco Technology was awarded 'Gold Supplier'.迈瑞医疗在武汉研发基地举办年度核心供应伙伴大会，超200家全球供应商参会；苏州亚科科技获评“金牌供应商”。
Corporate social responsibility and donations企业社会责任与捐赠
1 · 2024-03-21
▾
Mindray donates AEDs and training services to hometowns迈瑞向家乡捐赠AED及培训服务
2024-03-21Mindray executive VP Guo Yanmei donated 130 AEDs and training services to her hometown Fuyang on behalf of herself and her family.迈瑞常务副总裁郭艳美以个人及家人名义向家乡阜阳捐赠130台AED及教育培训服务。
Industry awards and market share行业奖项与市场份额
4 · 2024-03-27 → 2024-08-29
▾
Mindray wins National Brand Gold Award and achieves top domestic market shares迈瑞获国家品牌金奖，国内市场份额领先
2024-03-27Mindray won 'National Brand Gold Award' and 'Product Line No.1' in the 2023 China Medical Equipment Industry Data Survey Report; its monitors, defibrillators, anesthesia machines, ventilators, infusion pumps, and blood cell analyzers rank first domestically; ultrasound ranks second domestically and fourth globally.迈瑞在《2023年度中国医疗设备行业数据调研报告》中获评“民族品牌金奖”和“产品线第一名”；监护仪、除颤仪、麻醉机、呼吸机、输注泵、血液细胞分析设备国内第一，超声国内第二、全球第四。
2024-04-26FY2023: Mindray's monitors, anesthesia machines, ventilators, defibrillators reached top-3 global market share; ultrasound ranked top-3 globally for the first time.2023年迈瑞医疗监护仪、麻醉机、呼吸机、除颤仪全球市场占有率进入前三；超声市场占有率首次实现全球前三。
2024-06-20Mindray became the domestic ultrasound market leader for the first time, surpassing the former No.1 import brand; overseas, its monitors, anesthesia machines, ventilators, defibrillators, blood cell analyzers, and ultrasound ranked top 3 globally by market share in 2023.迈瑞医疗首次超越原市场第一的进口品牌，成为国内超声市场领头羊；海外市场监护仪、麻醉机、呼吸机、除颤仪、血球、超声2023年全球市占率位列前三。
2024-08-29Mindray's 2024 half-year report stated that the IFCC ranked Mindray's hs-cTnI reagents first among all global major IVD manufacturers in its updated performance reference table.迈瑞医疗2024半年报称，国际临床化学和实验室医学联盟（IFCC）更新的全球主要IVD厂家肌钙蛋白试剂性能参考表中，迈瑞hs-cTnI试剂排名第一。
Domestic policy response国内政策应对
11 · 2024-03-28 → 2026-03-28
▾
Mindray comments on equipment renewal policy, medical rectification, and VBP impact迈瑞对设备更新政策、医疗整顿及集采影响发表评论
2024-03-28Mindray commented on the State Council's 'Action Plan for Promoting Large-Scale Equipment Renewal and Old-for-New Consumer Goods' (March 13), noting provinces are surveying medical equipment upgrade needs; policy supports imaging, radiotherapy, surgical robots, and smart wearable devices.迈瑞就国务院3月13日发布的《推动大规模设备更新和消费品以旧换新行动方案》发表评论，指出各省已开始摸排医疗设备更新需求；政策支持影像、放疗、手术机器人、智能可穿戴设备。
2024-04-30Mindray management expects H2 2024 revenue growth to benefit from medical equipment renewal tenders after provincial surveys completed and funding in place.迈瑞医疗管理层预计2024年下半年业绩将受益于医疗设备更新招标，各省摸排已完成，配套资金到位后招标将启动。
2024-05-11Mindray stated at the performance briefing that the domestic medical industry rectification is normalizing, and medical equipment renewal projects are expected to contribute from H2 2024.迈瑞医疗在业绩说明会上表示，国内医疗行业整顿进入常态化，医疗设备更新项目预计2024年下半年开始贡献。
2024-06-25Four ministries (Ministry of Finance, NDRC, PBOC, NFRA) issued a notice on equipment-update loan interest subsidies, supporting medical device procurement funding; Mindray expected to benefit from policy tailwinds.财政部、国家发改委、中国人民银行、金融监管总局等四部门印发设备更新贷款财政贴息政策通知，保障医疗设备采购资金来源；迈瑞医疗有望受益。
2024-07-29Mindray guided that domestic medical equipment procurement tenders in H2 2024 will improve sequentially vs H1, supported by 300 billion yuan ultra-long-term special government bonds for equipment renewal.迈瑞医疗预计2024年下半年国内医疗设备采购招标环比上半年改善，得益于3000亿元超长期特别国债支持设备更新。
2024-12-31Mindray reported that in the 2024 Anhui provincial alliance volume-based procurement (VBP) for IVD reagents, its意向采购量 share for tumor markers (16 items) and thyroid function (9 items) reached 14.2% and 13.2% respectively, up from its 2023 domestic chemiluminescence market share of 8-9%.迈瑞医疗在2024年安徽省体外诊断试剂省际联盟集采中，肿瘤标志物16项和甲功9项的意向采购量占比分别为14.2%和13.2%，高于2023年国内化学发光业务8-9%的市占率。
2025-01-15In 2024 Anhui IVD provincial alliance centralized procurement, Mindray's intended procurement share for tumor markers (16 items) reached 14.2% and for thyroid function (9 items) 13.2%, up from 8-9% average domestic chemiluminescence market share in 2023. Company expects over 150 full-lab large automated流水线 installations in China this year, mostly in tertiary hospitals.2024年安徽IVD省际联盟集采中，公司肿瘤标志物16项意向采购量占比14.2%，甲功9项占比13.2%，高于2023年国内化学发光平均市占率8-9%；预计今年国内将实现150套以上全实验室大型自动化流水线装机，大部分在三级医院。
2025-05-19Mindray expects domestic business to see a major inflection point from Q3 2025, as medical equipment bidding recovers; medical special bonds in Q1 2025 reached RMB 56.512bn (+29.10% YoY).迈瑞医疗预计国内业务从2025年三季度起迎来重大拐点；2025年一季度医疗专项债规模565.12亿元（同比+29.10%）。
2025-10-14Mindray stated that centralized procurement (VBP) has significantly increased its domestic market share while gross margin remained stable, attributing this to core technology advantages.迈瑞医疗表示，集采政策使公司国内市场占有率大幅提升，但毛利率保持稳定，归因于核心技术优势。
2025-11-10Mindray disclosed that its domestic IVD business is still experiencing volume and price decline, with short-term recovery unlikely. The company aims to accelerate digital-intelligent transformation of equipment business and shift from price marketing to value marketing.迈瑞医疗披露国内IVD业务仍在经历量价齐跌，短期内很难复苏。公司计划加快设备业务数智化转型，从价格营销升级为价值营销。
2026-03-28Mindray stated that domestic market容量 has shrunk over the past two years across all business lines, though market share steadily increased; it expects domestic business to return to positive growth in 2026 and accelerate from 2027, driven by minimally invasive surgery and intervention consumables.迈瑞医疗表示，过去两年国内各业务线市场容量均出现萎缩，但公司市占率稳步提升；预计2026年国内业务有望实现正增长，2027年及之后在微创外科和微创介入耗材推动下加速增长。
AI and digital-intelligent productsAI与数智化产品
28 · 2024-04-03 → 2026-04-10
▾
Mindray launches AI-powered blood cell analyzer, ICU large model, and digital ecosystem迈瑞发布AI血细胞分析仪、重症大模型及数智化生态系统
2024-04-03Mindray's MC series fully automatic blood cell morphology analyzer, using AI for blood cell morphology examination, is described as a major breakthrough in AI clinical lab application.迈瑞医疗的MC系列全自动血细胞形态学分析仪，利用人工智能辅助血细胞形态学检查，被描述为人工智能在临床检验应用中的重大突破。
2024-06-13Mindray stated it has entered the next phase of digital-intelligent transformation, building an AI-empowered clinical digital-intelligent ecosystem via its 'Three Rui' ecosystem (RuiZhiLian, RuiYingCloud++, Mindray ZhiJian).迈瑞医疗表示已进入下一阶段数智化转型，通过“三瑞”生态系统（瑞智联、瑞影云++、迈瑞智检）构建AI全面赋能临床的数智化生态。
2024-06-18Mindray disclosed in its annual report for the first time its 'digital-intelligent' development journey: completed Phase 1 (broad innovative product portfolio) and Phase 2 (data-device-IT integration), now entering Phase 3 (AI-empowered clinical digital-intelligent ecosystem).迈瑞医疗在年报中首次披露“数智化”发展历程：已完成第一阶段（广阔创新产品布局）和第二阶段（数据、设备、IT互联融合），正进入第三阶段（AI全面赋能临床的数智化生态）。
2024-06-28Mindray launched AI-integrated medical devices in 2023, including MC series AI blood cell morphology analysis system, SV 900 critical care ventilator, and ultrasound full-stack intelligent solutions; its digital-intelligent solutions deployed in domestic and overseas高端 hospitals.迈瑞医疗2023年推出融合AI技术的医疗设备，包括MC系列人工智能血细胞形态分析系统、SV 900重症呼吸机、超声全栈式智能解决方案；数智化解决方案在国内外高端医院落地。
2024-06-29Mindray completed building an 'Equipment + IT + AI' intelligent medical ecosystem; its 'Three Rui' IT solutions (RuiZhiLian, Mindray ZhiJian, RuiYingCloud++) enable device interconnectivity and data sharing, supporting remote diagnosis and hierarchical medical services.迈瑞医疗完成“设备+IT+AI”智能医疗生态系统搭建；“三瑞”IT解决方案（瑞智联、迈瑞智检、瑞影云++）实现设备互联互通和数据共享，支持远程诊断和分级诊疗。
2024-08-26Mindray announced the upcoming release of NN-PBRTOC (Neural Network based PBRTQC), an AI-powered quality control model for sample testing, as part of its 'Device+IT+AI' smart healthcare ecosystem.迈瑞医疗宣布即将发布NN-PBRTOC（基于神经网络的PBRTQC）AI质控模型，作为其“设备+IT+AI”智能医疗生态系统的一部分。
2024-09-03Mindray and Tencent deepened strategic cooperation on large language models and cloud computing, jointly developing a medical ICU large model; previously co-developed an AI blood cell morphology analyzer (first AI Class III innovative device in IVD).迈瑞医疗与腾讯深化战略合作，在大语言模型及云计算方面合作，共同推进医疗重症大模型落地；此前联合研发了AI血细胞形态学分析仪（国内IVD首个AI三类创新器械）。
2024-09-11Mindray disclosed that its AI blood cell morphology analyzer (MC series) multi-center study was published in Clinica Chimica Acta (IF 5.0, JCR Q1) in January 2024, reducing reading time from 25-30 min to 30 seconds.迈瑞医疗披露其AI血细胞形态学分析仪（MC系列）多中心研究结果于2024年1月发表在Clinica Chimica Acta（IF 5.0，JCR一区），阅片时间从25-30分钟缩短至半分钟。
2024-09-24Mindray announced it will release the industry's first ICU decision-support system based on AI large model by end of 2024.迈瑞医疗宣布将于2024年底发布行业首个基于AI大模型技术的重症决策辅助系统。
2024-10-29Mindray partnered with Tencent Health to launch an ICU large model (AI) in Q3 2024, aiming to improve diagnosis and treatment efficiency.迈瑞医疗联合腾讯健康在2024年第三季度推出重症大模型（AI），助力提升诊疗效率和质量。
2024-11-05Mindray and Tencent Health jointly launched a critical care large model, integrating with clinical information systems (CIS) to enable continuous dynamic monitoring, standardized cluster treatment, and automatic output of accurate medical records.迈瑞医疗联合腾讯健康推出重症大模型，与临床信息系统融合，实现连续动态监测、规范集束化诊疗及自动输出准确病历等功能。
2024-11-28Mindray detailed its digital transformation: the 'San Rui' ecosystem (RuiZhiLian for device connectivity, Mindray ZhiJian for lab management, RuiYingCloud++ for imaging) has been deployed at high-end domestic and international customers. The company is building a vertical medical large model with self-learning AI capabilities.迈瑞医疗详述数智化转型：“三瑞”生态系统（瑞智联、迈瑞智检、瑞影云++）已在国内外高端客户部署，公司正在搭建医疗垂直领域大模型，具备自我学习AI能力。
2024-12-14Mindray and Tencent jointly launched the world's first clinically deployed critical care large model, 'Qiyuan Critical Care Large Model', in Beijing. It can回溯 patient data in 5 seconds, generate clinical notes in 1 minute, and provide 95% accurate knowledge queries.迈瑞医疗与腾讯在北京联合发布全球首个临床落地的重症医疗大模型——'启元重症大模型'，可在5秒内回溯患者病情、1分钟生成病历、提供准确率95%的重症知识查询。
2025-01-18Company unveiled 'Device + Consumables + IT + AI' four-in-one solution and Qiyuan ICU large model, achieving 95% accuracy in critical care knowledge queries, patient digital twin in 5 seconds, and clinical document generation in 1 minute.公司推出“设备+耗材+IT+AI”四位一体解决方案及启元重症大模型，重症知识查询准确率95%，5秒内还原患者数字画像，1分钟生成病历文档。
2025-02-12Mindray stated it is building a department-level vertical large model for clinical applications, welcomes base model advancements, and embraces new technologies to co-build a medical digital intelligence ecosystem; no specific partnership with DeepSeek confirmed.迈瑞医疗表示正在打造科室级垂直大模型，欢迎基座大模型发展，拥抱新技术共建医疗数智生态；未确认与DeepSeek的具体合作。
2025-03-07Mindray and Nanshan District People's Hospital jointly established an AI Smart Joint Laboratory, focusing on emergency 5G integration, Qiyuan severe disease large model, laboratory clinical verification, and digital imaging, aiming to create a replicable smart medical 'Nanshan Model'.迈瑞医疗与南山区人民医院共同成立AI智慧联合实验室，围绕急救5G一体化、启元重症大模型、实验室临床验证和数字化影像学等领域攻关，打造可复制推广的智慧医疗“南山模式”。
2025-04-03Mindray launched 'Ruiying AI+' solution on its 'Ruiying Cloud++' platform in partnership with DeepSeek, focusing on medical imaging AI applications such as an ultrasound knowledge base.迈瑞医疗在“瑞影云++”平台上携手DeepSeek发布“瑞影·AI+”解决方案，聚焦医学影像AI应用，如超声知识库。
2025-04-09At CMEF 2025, Mindray showcased over 40 innovative products, including the Qiyuan重症大模型 (Qiyuan Critical Care Large Model), the first clinically deployed critical care large model globally, and full-scenario AI solutions 'Digital Intelligence Lab' and 'Ruiying Ecosystem'.在2025年CMEF上，迈瑞医疗展出40多款创新产品，包括全球首个投入临床的重症大模型“启元重症大模型”，以及全场景AI解决方案“数智实验室”和“瑞影生态”。
2025-04-10At the 7th World Health Expo, Mindray SVP Li Xinsheng outlined a dual-drive model of 'specialty thinking training + precise data supply' for medical AI, referencing the Qiyuan Critical Care Large Model.在第七届世界大健康博览会上，迈瑞医疗高级副总裁李新胜提出医疗AI的“专科思维训练+精准数据供给”双轮驱动模式，并以启元重症大模型为例。
2025-05-06Mindray launched the 'Qiyuan' (Genesis) severe-care medical large model in December 2024, the world's first clinically deployed severe-care AI model; it can retrieve and integrate patient history within 5 seconds and predict trends.迈瑞医疗于2024年12月发布全球首个临床落地的重症医疗大模型“启元”，可在5秒内回溯整合患者病情并预测趋势。
2025-06-29Mindray hosted an investor day (May 19-Jun 27) attended by 383 institutions, detailing digital-intelligent transformation with 'equipment + IT + AI' and 'equipment + consumables' solutions; AI reading accuracy exceeds 98% with 10x efficiency vs manual; new hormone reagent suite to launch in 2025.迈瑞于5月19日至6月27日举办投资者开放日，接待383家机构，详述“设备+IT+AI”和“设备+耗材”的数智化转型方案；AI阅片准确率超98%，效率较人工提升10倍；2025年将发布全新一代激素套餐产品。
2025-07-30Mindray launched the 'Ruiying Ecosystem' (瑞影生态), an ultrasound imaging ecosystem integrating 'device + IT + AI', covering POC, cardiovascular, obstetrics/gynecology, and AI applications.迈瑞医疗发布“瑞影生态”，整合“设备+IT+AI”的超声影像生态系统，覆盖POC、心血管、妇产及AI应用。
2025-08-27Completed 'Device + IT + AI' digital healthcare ecosystem; launched Qiyuan AI vertical domain large model; released world's first clinically deployed critical care large model.完成“设备+IT+AI”数智医疗生态系统搭建；发布启元AI垂域大模型；推出全球首个临床落地的重症医疗大模型。
2025-09-01Mindray launched the world's first clinically deployed critical care large model, the Qiyuan Critical Care Large Model.迈瑞医疗发布了全球首个临床落地的重症医疗大模型——启元重症大模型。
2025-09-01Mindray's 'Ruiying Cloud++' partnered with DeepSeek to release the 'Ruiying·AI+' solution in medical imaging.迈瑞医疗“瑞影云++”已携手DeepSeek，正式发布“瑞影·AI+”解决方案。
2026-01-09Mindray confirmed it has no involvement in brain-computer interface (BCI) business, and has completed its 'Device + IT + AI' digital medical ecosystem with the 'Rui Zhi, Rui Jian, Rui Ying' specialized information systems and the Qiyuan AI vertical large model.迈瑞确认不涉及脑机接口业务，已完成“设备+IT+AI”数智医疗生态系统搭建，包括“瑞智、瑞检、瑞影”专科信息系统和启元AI垂域大模型。
2026-04-01Mindray released the world's first clinically deployed critical care large model, the Qiyuan Critical Care Large Model, and established a dedicated animal medical subsidiary.迈瑞医疗发布了全球首个临床落地的重症医疗大模型——启元重症大模型，并专门成立了动物医疗子公司。
2026-04-10At CMEF 2026, Mindray showcased the Qiyuan medical large model matrix and full-process digital-intelligent medical solutions, advancing its 'Device + IT + AI' integrated strategy.在第93届CMEF上，迈瑞医疗展示了启元医疗大模型矩阵及全流程数智医疗解决方案，推进“设备+IT+AI”一体化战略。
Annual and quarterly financial results年度与季度财务业绩
22 · 2024-04-26 → 2026-05-01
▾
Mindray reports FY2023, FY2024, FY2025, and quarterly results with revenue and profit trends迈瑞公布2023、2024、2025财年及季度业绩，展示收入与利润趋势
2024-04-26FY2023: revenue RMB 34.932 billion (+15.04% YoY), net profit RMB 11.582 billion (+20.56% YoY); proposed dividend RMB 1.5 per 10 shares, total cash dividend RMB 1.819 billion.2023年年报：营收349.32亿元（同比+15.04%），净利润115.82亿元（同比+20.56%）；拟10派15元，合计派发现金红利18.19亿元。
2024-04-26Q1 2024: revenue RMB 9.373 billion (+12.06% YoY), net profit RMB 3.16 billion (+22.9% YoY); international market grew nearly 30% (developing countries >30%).2024年一季报：营收93.73亿元（同比+12.06%），净利润31.6亿元（同比+22.9%）；国际市场增长近30%（发展中国家增长超30%）。
2024-05-07Mindray released 2023 annual report and 2024 Q1 report: 2023 revenue 34.932 billion yuan (+15.04% YoY), net profit 11.582 billion yuan (+20.56% YoY); 2024 Q1 revenue 9.373 billion yuan (+12.06% YoY), net profit 3.160 billion yuan (+22.90% YoY).迈瑞医疗发布2023年年报和2024年一季报：2023年营收349.32亿元（同比+15.04%），净利润115.82亿元（同比+20.56%）；2024年一季度营收93.73亿元（同比+12.06%），净利润31.60亿元（同比+22.90%）。
2024-06-20Mindray's 2023 revenue growth fell below 20% for the first time in 6 years; life information & support segment grew only 13.8%, while in-vitro diagnostics maintained over 20% growth; net profit exceeded 100 billion yuan for the first time.迈瑞医疗2023年营收增速6年来首次跌破20%；生命信息与支持业务仅增长13.8%，体外诊断业务保持20%以上增长；净利润首次突破百亿元。
2024-08-29Mindray released 2024 half-year results: revenue 20.531 billion yuan (+11.12% YoY), net profit 7.561 billion yuan (+17.37% YoY), and proposed an interim dividend of 4.06 yuan per 10 shares (total ~4.923 billion yuan).迈瑞医疗发布2024年半年报：营业收入205.31亿元（同比+11.12%），净利润75.61亿元（同比+17.37%），拟每10股派发现金红利40.60元（合计约49.23亿元）。
2024-09-01Mindray released 2024H1 results: revenue 20.531B yuan (+11.12% YoY), net profit 7.561B yuan (+17.37% YoY); IVD revenue 7.658B yuan (+28.16%), chemiluminescence >30%; overseas IVD >30%; minimally invasive surgery >90%; high-end ultrasound >40%.迈瑞医疗发布2024年上半年业绩：营收205.31亿元（同比+11.12%），净利润75.61亿元（同比+17.37%）；体外诊断收入76.58亿元（+28.16%），化学发光>30%；海外IVD>30%；微创外科>90%；高端超声>40%。
2024-10-12Mindray reported strong H1 2024 results: revenue up 11.12% YoY to 20.531 billion yuan, net profit up 17.37% to 7.561 billion yuan; IVD business grew 28.16%.迈瑞医疗2024年上半年业绩强劲：营收同比增长11.12%至205.31亿元，净利润同比增长17.37%至75.61亿元；体外诊断业务增长28.16%。
2024-10-29Mindray reported Q3 2024 results: Q3 revenue 8.954 billion yuan (+1.43% YoY), net profit 3.076 billion yuan (-9.31% YoY); first-ever quarterly net profit decline since listing. 9M revenue 29.485 billion yuan (+7.99%), net profit 10.637 billion yuan (+8.16%).迈瑞医疗发布2024年三季报：第三季度营收89.54亿元（同比+1.43%），净利润30.76亿元（同比-9.31%），上市以来首次单季净利润下滑；前三季度营收294.85亿元（+7.99%），净利润106.37亿元（+8.16%）。
2024-11-01Mindray reported 2024 Q1-Q3 revenue of RMB 29.485 billion, +8.0% YoY; net profit of RMB 10.637 billion, +8.2% YoY. In vitro diagnostics (IVD) revenue grew >20% YoY, becoming the largest revenue segment. Q3 single-quarter net profit fell 9.31% YoY, the first decline since listing.迈瑞医疗公布2024年前三季度营收294.85亿元，同比增长8.0%；净利润106.37亿元，同比增长8.2%。体外诊断业务收入同比增长超20%，成为第一大营收板块。第三季度单季净利润同比下降9.31%，为上市以来首次下滑。
2025-04-28Mindray reported Q1 2025 revenue of RMB 8.237 billion (-12.12% YoY) and net profit of RMB 2.629 billion (-16.81% YoY); QoQ revenue grew 13.76% and net profit surged 154.85%, with domestic revenue up over 50% QoQ.迈瑞医疗2025年一季度营收82.37亿元（同比-12.12%），净利润26.29亿元（同比-16.81%）；环比营收增长13.76%，净利润增长154.85%，国内收入环比增长超50%。
2025-04-28Mindray reported FY2024 revenue of RMB 36.726 billion (+5.14% YoY) and net profit of RMB 11.668 billion (+0.74% YoY), marking the 7th consecutive year of dual growth since listing.迈瑞医疗2024年全年营收367.26亿元（同比+5.14%），净利润116.68亿元（同比+0.74%），上市以来连续第7年双增长。
2025-05-01Mindray 2024 annual results: revenue RMB 36.726bn (+5.14% YoY), net profit RMB 11.668bn (+0.74% YoY); 2025Q1 revenue RMB 8.237bn (-12.12% YoY), net profit RMB 2.629bn (-16.81% YoY).迈瑞医疗2024年报：营收367.26亿元（同比+5.14%），净利润116.68亿元（同比+0.74%）；2025年一季度营收82.37亿元（同比-12.12%），净利润26.29亿元（同比-16.81%）。
2025-07-02Mindray reported 2024 annual revenue of 36.73 billion yuan, up 5.14% YoY, and net profit of 11.67 billion yuan, up 0.74% YoY, both the lowest since its 2018 A-share listing; Q1 2025 revenue fell 12.12% to 8.237 billion yuan, net profit fell 16.81% to 2.629 billion yuan.迈瑞医疗公布2024年营业收入367.3亿元，同比增长5.14%，净利润116.7亿元，同比增长0.74%，均为2018年A股上市以来最低；2025年一季度营收同比下降12.12%至82.37亿元，净利润下降16.81%至26.29亿元。
2025-08-272025 H1 results: revenue RMB 16.743 billion (-18.45% YoY); net profit RMB 5.069 billion (-32.96% YoY); second interim dividend of RMB 1.31 per 10 shares (total RMB 1.588 billion).2025年上半年业绩：营业收入167.43亿元（同比-18.45%）；净利润50.69亿元（同比-32.96%）；第二次中期分红每10股派13.10元（合计15.88亿元）。
2025-09-08Mindray's H1 2025 revenue was 16.743 billion yuan, down 18.45% YoY; net profit margin fell to 31.25% from 36.90%; gross margin fell to 61.67% from 66.25%; operating cash flow was 3.922 billion yuan, down 53.83%.迈瑞医疗2025年上半年营收167.43亿元，同比下降18.45%；净利率从36.90%降至31.25%；毛利率从66.25%降至61.67%；经营现金流净额39.22亿元，同比下降53.83%。
2025-10-29Mindray reported Q3 2025 revenue of RMB 9.091 billion, +1.53% YoY; net profit of RMB 2.501 billion, -18.69% YoY. 9M 2025 revenue was RMB 25.834 billion, -12.38% YoY; net profit was RMB 7.570 billion, -28.83% YoY. Contract liabilities reached RMB 2.263 billion, +31.45% YoY.迈瑞医疗2025年第三季度营收90.91亿元，同比增长1.53%；净利润25.01亿元，同比下降18.69%。前三季度营收258.34亿元，同比下降12.38%；净利润75.70亿元，同比下降28.83%。合同负债达22.63亿元，同比增长31.45%。
2025-11-04Mindray reported Q1-Q3 2025 revenue of RMB 25.834 billion, down 12.38% YoY; net profit of RMB 7.570 billion, down 28.83% YoY. Q3 2025 revenue was RMB 9.09 billion, up 1.5% YoY and 6.9% QoQ.迈瑞医疗公布2025年前三季度营收258.34亿元，同比下降12.38%；净利润75.70亿元，同比下降28.83%。2025年第三季度营收90.9亿元，同比增长1.5%，环比增长6.9%。
2025-12-03Mindray's 2025 Q3 results: revenue 25.834 billion yuan, down 12.38% YoY; net profit 7.570 billion yuan; first revenue and profit decline since 2018 IPO. Q2 revenue fell 18.45%, net profit fell 32.96%.迈瑞医疗2025年前三季度营收258.34亿元，同比下滑12.38%；净利润75.70亿元；自2018年上市以来首次营收净利双降。二季度营收下滑18.45%，净利润下滑32.96%。
2026-03-30Mindray reported 2025 annual results: revenue 33.282 billion yuan, down 9.38% YoY; net profit 8.136 billion yuan, down 30.28% YoY; proposed cash dividend of 0.31 yuan per share (含税).迈瑞医疗发布2025年年报：营业收入332.82亿元，同比下降9.38%；净利润81.36亿元，同比下降30.28%；拟每10股派发现金红利3.1元（含税）。
2026-04-01Mindray's 2025 annual report: revenue of RMB 33.282 billion, down 9.38% YoY; net profit of RMB 8.136 billion, down 30.28% YoY. International revenue exceeded 53% of total for the first time, reaching RMB 17.65 billion, up 7.4%.迈瑞医疗2025年年报：营业收入332.82亿元，同比下降9.38%；归母净利润81.36亿元，同比下降30.28%。国际业务收入首次突破总营收53%，达176.5亿元，同比增长7.4%。
2026-04-28Mindray 2026 Q1 results: revenue RMB 8.352 billion, up 1.39% YoY; net profit RMB 2.330 billion, down 11.37% YoY. International revenue grew 15.70% to RMB 4.449 billion, accounting for 53% of total.迈瑞医疗2026年一季度业绩：营业收入83.52亿元，同比增长1.39%；归母净利润23.30亿元，同比下降11.37%。国际业务收入44.49亿元，同比增长15.70%，占比53%。
2026-05-01Mindray Bio-Medical reported 2026Q1 revenue of RMB 8.352 billion, up 1.39% YoY; net profit of RMB 2.33 billion, down 11.37% YoY; operating cash flow of RMB 1.381 billion, down 7.59% YoY.迈瑞医疗2026年一季度实现营业收入83.52亿元，同比增长1.39%；归母净利润23.3亿元，同比下降11.37%；经营性现金流净额13.81亿元，同比下降7.59%。
R&D investment and centers研发投入与中心
6 · 2024-04-26 → 2026-02-26
▾
Mindray increases R&D spending and expands global R&D centers迈瑞增加研发投入并扩展全球研发中心
2024-04-26FY2023: R&D spending RMB 3.779 billion (+18.43% YoY), 10.82% of revenue; global R&D centers expanded to 12; total patent applications 10,090 (7,222 invention), granted patents 4,767 (2,226 invention).2023年研发投入37.79亿元（同比+18.43%），占营收10.82%；全球研发创新中心增至12个；累计申请专利10090件（发明专利7222件），授权专利4767件（发明专利授权2226件）。
2024-05-07Mindray's 2023 annual report showed R&D expenditure of 3.433 billion yuan, up 17.45% YoY; the company's global R&D innovation centers expanded to 12, with R&D spending of 3.779 billion yuan in 2023 (10.82% of revenue).迈瑞医疗2023年年报显示研发投入34.33亿元，同比增长17.45%；全球研发创新中心扩充至12个，2023年研发投入37.79亿元（占营收10.82%）。
2025-02-17Mindray disclosed that R&D investment in the first three quarters of 2024 reached 2.84 billion yuan, accounting for 9.6% of revenue; the company maintains annual R&D spending at about 10% of revenue.迈瑞医疗披露2024年前三季度研发投入达28.4亿元，占营收比重9.6%；公司保持年研发投入约占营收10%。
2025-04-28Mindray's R&D spending in FY2024 was RMB 4.008 billion, 10.91% of revenue; Q1 2025 R&D was RMB 847 million, 10.28% of revenue.迈瑞医疗2024年研发投入40.08亿元，占营收10.91%；2025年一季度研发投入8.47亿元，占营收10.28%。
2025-08-27R&D spending in H1 2025 reached RMB 1.777 billion, accounting for 10.61% of revenue; full-year 2024 R&D spending was RMB 3.666 billion, up 6.79% YoY.2025年上半年研发投入17.77亿元，占营收10.61%；2024年全年研发投入36.66亿元，同比增长6.79%。
2026-02-26In the first half of 2025, Mindray's R&D expenditure was 1.607 billion yuan, a year-on-year decrease of 9.5%.2025年上半年，迈瑞医疗研发投入16.07亿元，同比减少9.5%。
International customer expansion国际客户拓展
7 · 2024-04-26 → 2026-04-10
▾
Mindray wins large US monitoring order, breaks into high-end overseas customers迈瑞赢得美国大额监护订单，突破海外高端客户
2024-04-26FY2023: In the US, Mindray won a single monitoring equipment order worth nearly USD 30 million, its largest single monitoring order in the US market.2023年迈瑞医疗在美国赢得某集团近3000万美元的监护设备订单，为其在美国市场迄今为止最大的单笔监护订单。
2024-04-26FY2023: IVD business broke through over 450 new high-end customers, including 106 third-party chain labs; overseas IVD compound growth exceeded 30% for two consecutive years.2023年体外诊断业务突破超过450家全新高端客户，包括106家第三方连锁实验室；海外体外诊断连续两年复合增速超过30%。
2024-05-07Mindray's 2023 annual report noted that it has covered 80 of the global top 100 hospitals (Newsweek ranking).迈瑞医疗2023年年报显示已覆盖《新闻周刊》全球TOP100医院中的80家。
2025-09-01Mindray broke into over 160 new high-end overseas IVD customers, achieved cross-selling in 50+ existing high-end customers including nearly 30 third-party chain labs, and broke into 50 new high-end imaging customers with cross-selling in 130 more.迈瑞医疗在体外诊断领域成功开拓160余家全新高端客户，在50余家已有高端客户实现产品横向渗透（含近30家第三方连锁实验室）；医学影像领域突破50家全新高端客户及130家高端客户的横向突破。
2025-09-03Mindray's digital solution deployed at St Thomas' Hospital (UK's top-ranked hospital), with VS9 vital signs monitors achieving large-scale installation.迈瑞医疗的数智化解决方案已在全英国综合排名第一的圣托马斯医院落地，VS9生命体征监护仪实现规模化装机。
2025-10-14Mindray disclosed that its IVD business in the Czech Republic has achieved a 25% market share for hematology products, with installations at teaching hospitals including Nemocnice Na Homolce and Fakultní nemocnice Brno, and an M980 chemistry-immunology cascade line installed at BH Olomouc hospital.迈瑞医疗披露其在捷克IVD业务血球产品市占率达25%，已在Nemocnice Na Homolce、Fakultní nemocnice Brno等教学医院装机，M980化免级联流水线在BH Olomouc医院装机。
2026-04-10Mindray deepened cooperation with IHH Healthcare Group in Malaysia, India, Turkey, Bulgaria, and the Netherlands; also partnered with Innoquest Pathology in Malaysia for hematology and chemistry analyzer installations.迈瑞医疗与IHH医疗保健集团在马来西亚、印度、土耳其、保加利亚和荷兰深化合作，并与马来西亚Innoquest Pathology合作安装血球和化免设备。
Dividend and shareholder returns分红与股东回报
15 · 2024-04-26 → 2026-06-03
▾
Mindray declares multiple dividends and commits to high payout ratio迈瑞多次分红并承诺高派息率
2024-04-26FY2023: total cash dividend (including Q3 2023 interim) reached RMB 7.032 billion, payout ratio 60.72%; cumulative dividends since IPO ~RMB 24.8 billion (incl. RMB 2 billion buyback), 4x IPO proceeds.2023年度现金分红（含三季度已分配）合计70.32亿元，分红比例60.72%；上市以来累计分红总额近248亿元（含回购20亿元），为IPO募资额的4倍。
2024-05-19Mindray's cumulative dividends over 6 years (2018-2023) reached nearly 24.8 billion yuan, 4.2 times its IPO proceeds; 2023 dividend per 10 shares was 15 yuan, totaling 1.819 billion yuan.迈瑞医疗六年（2018-2023）累计分红近248亿元，是IPO募资额的4.2倍；2023年每10股派15元，合计18.19亿元。
2024-05-20Mindray's 2023 annual general meeting approved the profit distribution plan: 1.5 yuan per 10 shares (total 1.819 billion yuan), and authorized the board to formulate an interim dividend plan.迈瑞医疗2023年度股东大会审议通过利润分配预案：每10股派15元（合计18.19亿元），并授权董事会制定中期分红方案。
2024-09-02Mindray's major shareholder committed not to reduce holdings for the next six months and declared an interim dividend of 4.06 yuan per share.迈瑞医疗大股东承诺未来半年不减持，并派发中期股息每股4.06元。
2024-10-29Mindray announced a second interim dividend for 2024: 16.5 yuan per 10 shares (tax included), totaling approximately 2.001 billion yuan.迈瑞医疗公布2024年第二次中期利润分配方案：每10股派发现金股利16.5元（含税），合计约20.01亿元。
2024-11-01Mindray announced its second interim dividend for 2024: RMB 1.65 per 10 shares (Q3), following RMB 4.06 per 10 shares at mid-year. Total cash dividends for the first three quarters exceeded RMB 6.907 billion, representing 64.9% of attributable net profit.迈瑞医疗宣布2024年第二次中期分红：每10股派16.5元（三季度），此前中报已每10股派40.6元。前三季度累计派发现金红利超69.07亿元，占归属净利润的64.9%。
2025-04-24Mindray disclosed cumulative dividends of RMB 31.722 billion (including RMB 2 billion in buybacks) since listing, 5 times the IPO amount; 2024 second interim dividend was RMB 2 billion.迈瑞医疗披露上市以来累计分红317.22亿元（含回购20亿元），为IPO募资额5倍；2024年第二次中期分红20亿元。
2025-04-29Mindray committed to an annual dividend payout ratio of no less than 65% for the next three years; FY2024 total cash dividend planned at RMB 7.602 billion (65.15% payout ratio).迈瑞医疗承诺未来三年每年分红比例不低于65%；2024年度累计现金分红计划76.02亿元（分红比例65.15%）。
2025-05-22Mindray announced a record-high cash dividend of RMB 19.70 per 10 shares (including RMB 5.60 for FY2024 and RMB 14.10 for 2025 interim), totaling approximately RMB 2.389bn; 2025-2027 annual cash dividend ratio set at no less than 65% of distributable profit.迈瑞医疗宣布创纪录分红方案：每10股派发现金红利19.70元（含2024年度5.60元和2025年中期14.10元），合计约23.89亿元；2025-2027年每年现金分红比例不低于65%。
2025-08-27Cumulative cash dividends since listing reached RMB 35.7 billion (including RMB 2 billion share buyback), 6 times the IPO proceeds of RMB 5.934 billion; 2025 total interim dividends RMB 3.298 billion, 65.06% of H1 net profit.上市以来累计分红总额达357亿元（含回购20亿元），为IPO募资额59.34亿元的6倍；2025年中期累计分红32.98亿元，占上半年净利润65.06%。
2025-09-10Mindray implemented its second interim dividend for 2025, bringing total 2025 cash dividends to 3.298 billion yuan (65.06% of H1 net profit); cumulative dividends since listing reached 35.7 billion yuan (including 2 billion yuan in buybacks).迈瑞医疗实施2025年第二次中期分红，2025年累计现金分红32.98亿元（占半年度净利润65.06%）；上市以来累计分红总额达357亿元（含回购20亿元）。
2025-10-29Mindray announced a third interim dividend for 2025 of RMB 13.50 per 10 shares, totaling approximately RMB 1.637 billion.迈瑞医疗宣布2025年第三次中期利润分配方案，每10股派发现金股利13.50元，合计约16.37亿元。
2025-11-04Mindray announced its third interim dividend for 2025: RMB 1.35 per 10 shares (tax incl.), totaling RMB 1.637 billion, based on 1,212,441,394 shares. Record date Nov 11, ex-dividend Nov 12. Cumulative 2025 dividends reach ~RMB 4.935 billion, 65.19% of Q1-Q3 net profit.迈瑞医疗宣布2025年第三次中期分红：每10股派发现金股利13.50元（含税），合计约16.37亿元，以总股本1,212,441,394股为基数。股权登记日11月11日，除权除息日11月12日。2025年累计分红约49.35亿元，占前三季度净利润的65.19%。
2026-04-28Mindray proposed a cash dividend of RMB 12.5 per 10 shares (total ~RMB 1.516 billion) for Q1 2026, representing 65.05% of Q1 net profit.迈瑞医疗拟向全体股东每10股派发现金股利12.5元（含税），预计总派发金额约15.16亿元，占一季度归母净利润的65.05%。
2026-06-03Mindray completed 2025 annual and 2026 first interim dividend distribution, totaling approximately RMB 1.892 billion (RMB 15.60 per 10 shares).迈瑞医疗完成2025年度及2026年第一次中期权益分派，合计派发现金红利约18.92亿元（每10股派现15.60元）。
Product portfolio and segment disclosure产品组合与分部披露
17 · 2024-05-07 → 2026-04-29
▾
Mindray discloses medical imaging, IVD, and life support segment revenues迈瑞披露医学影像、IVD及生命信息与支持分部收入
2024-05-07Mindray disclosed on the investor interactive platform that its medical imaging products include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS, covering from ultra-premium to low-end series.迈瑞医疗在投资者互动平台披露，其医学影像产品包括超声诊断系统、数字X射线成像系统和PACS，覆盖从超高端到低端全系列。
2024-05-07Mindray's 2023 annual report disclosed segment revenue: Life Information & Support 15.23 billion yuan, In Vitro Diagnostics 12.42 billion yuan, Medical Imaging 7.03 billion yuan; ultrasound high-end models grew >20%, ultrasound market ranked first in China and third globally.迈瑞医疗2023年年报披露分业务收入：生命信息与支持152.3亿元，体外诊断124.2亿元，医学影像70.3亿元；超声高端型号增长超20%，超声市场地位国内第一、全球第三。
2024-08-29Mindray's 2024 half-year report showed IVD revenue of 7.658 billion yuan (+28.16% YoY), with chemiluminescence growing over 30%; medical imaging revenue of 4.274 billion yuan (+15.49% YoY), with premium ultrasound up over 40%; life information & support revenue of 8.009 billion yuan (-7.59% YoY), but minimally invasive surgery grew over 90%.迈瑞医疗2024半年报显示：体外诊断收入76.58亿元（同比+28.16%），化学发光增长超30%；医学影像收入42.74亿元（同比+15.49%），高端超声增长超40%；生命信息与支持收入80.09亿元（同比-7.59%），但微创外科增长超90%。
2024-10-29Mindray's IVD business became the largest revenue segment for the first time in 9M 2024, growing over 20% YoY to 11.4 billion yuan, surpassing Life Information & Support (10.89 billion yuan).迈瑞医疗体外诊断业务在2024年前三季度首次成为第一大收入板块，同比增长超20%至114亿元，超越生命信息与支持业务（108.9亿元）。
2024-10-29Mindray's Life Information & Support segment declined over 10% in 9M 2024, with domestic sales down over 20% due to delayed hospital procurement; international segment grew over 10%.迈瑞医疗生命信息与支持产线前三季度下滑超10%，国内因医院招标推迟下滑超20%，国际产线增长超10%。
2025-04-28Mindray's IVD (in-vitro diagnostics) business became the largest revenue segment in FY2024, with revenue of RMB 13.765 billion (+10.82% YoY); MT 8000 full-lab intelligent流水线 (automated line) installed nearly 190 sets, and chemiluminescence instruments installed 1,800 units.迈瑞医疗体外诊断业务2024年收入137.65亿元（同比+10.82%），首次成为第一大业务板块；MT 8000全实验室智能化流水线装机近190套，化学发光仪器装机1800台。
2025-04-28Mindray's life information & support business revenue in FY2024 was RMB 13.557 billion, with minimally invasive surgery growing over 30% YoY; medical imaging revenue was RMB 7.498 billion (+6.6% YoY).迈瑞医疗2024年生命信息与支持业务收入135.57亿元，微创外科同比增长超30%；医学影像收入74.98亿元（同比+6.6%）。
2025-05-01Mindray's IVD (in-vitro diagnostics) business became the largest segment in 2024 with revenue of RMB 13.765bn (+10.82% YoY), overtaking the life information & support segment (RMB 13.557bn, -11.11% YoY).迈瑞医疗2024年体外诊断业务收入137.65亿元（同比+10.82%），首次超过生命信息与支持业务（135.57亿元，同比-11.11%），成为第一大业务板块。
2025-06-25Mindray's 2024 IVD revenue reached RMB 13.765 billion (+10.82% YoY), becoming the largest revenue contributor; international IVD grew over 30%. Medical imaging revenue was RMB 7.498 billion (+6.6% YoY), with international imaging up over 15%.迈瑞2024年IVD业务营收达137.65亿元（同比增长10.82%），成为最大收入贡献者；国际IVD增长超30%。医学影像业务营收74.98亿元（同比增长6.6%），国际影像增长超15%。
2025-07-02Mindray's Life Information & Support segment revenue fell 11.11% to 13.557 billion yuan in 2024, the only negative-growth segment.迈瑞医疗生命信息与支持业务2024年营收同比下降11.11%至135.57亿元，成为唯一负增长板块。
2025-07-09Mindray's 2024 IVD revenue reached 13.765 billion yuan, up 10.82% YoY, with international IVD revenue up over 30%; medical imaging revenue was 7.498 billion yuan, up 6.60%, with international imaging up over 15% and ultra-premium ultrasound Resona A20 generating over 400 million yuan in its first year.迈瑞医疗2024年体外诊断业务收入137.65亿元，同比增长10.82%，其中国际体外诊断业务增长超30%；医学影像业务收入74.98亿元，同比增长6.60%，其中国际医学影像增长超15%，超高端超声Resona A20上市首年收入超4亿元。
2025-08-27H1 2025 IVD revenue RMB 6.424 billion (-16.11% YoY); international IVD achieved double-digit growth, international chemiluminescence grew over 20%; 13 sets of MT 8000 full-lab automation lines sold overseas.2025年上半年体外诊断业务收入64.24亿元（同比-16.11%）；国际体外诊断双位数增长，国际化学发光增长超20%；海外销售13套MT 8000全实验室智能化流水线。
2025-08-27H1 2025 medical imaging revenue RMB 3.312 billion (-22.51% YoY); international imaging achieved mid-to-high single-digit growth, international revenue share reached 62%; premium ultrasound series revenue nearly RMB 400 million.2025年上半年医学影像业务收入33.12亿元（同比-22.51%）；国际影像中高个位数增长，国际收入占比达62%；超高端超声系列收入近4亿元。
2025-08-27H1 2025 life information & support revenue RMB 5.479 billion (-31.59% YoY); minimally invasive surgery core consumables (ultrasonic knife, endoscope, stapler) began volume growth in domestic market in 2025.2025年上半年生命信息与支持业务收入54.79亿元（同比-31.59%）；微创外科核心耗材（超声刀、腔镜、吻合器）2025年在国内开始放量。
2026-04-09Mindray restructured its reporting segments into four lines: IVD, Life Information & Support, Medical Imaging, and Emerging Business (minimally invasive surgery, intervention, animal medical). Emerging Business 2025 revenue was RMB 5.378 billion, up 38.85%.迈瑞医疗将业务线重组为四大板块：体外诊断、生命信息与支持、医学影像和新兴业务（微创外科、微创介入、动物医疗）。新兴业务2025年营收53.78亿元，同比增长38.85%。
2026-04-29Mindray Q1 2026 IVD revenue reached RMB 3.193 billion, up 4.96% YoY, accounting for 38% of total revenue. International IVD revenue grew over 20%, with immunology up over 30%.迈瑞医疗2026年一季度IVD业务营收31.93亿元，同比增长4.96%，占总营收38%。国际IVD业务营收同比增长超20%，其中免疫业务同比增长超30%。
2026-04-29Mindray Q1 2026 Emerging Business revenue grew over 18% YoY; minimally invasive intervention revenue grew 25%; animal medical revenue achieved double-digit growth.迈瑞医疗2026年一季度新兴业务收入同比增长超18%，微创介入业务收入同比增长25%，动物医疗收入实现同比双位数增长。
Executive appointments and board changes高管任命与董事会变动
7 · 2024-05-11 → 2026-05-19
▾
Mindray appoints new senior managers, elects board members, and changes committee composition迈瑞任命新高管、选举董事会成员并调整委员会组成
2024-05-11Mindray held a performance briefing on May 11, 2024, with chairman Li Xiting, GM Wu Hao, CFO Zhao Yun, board secretary Li Wenmei, and independent director Liang Huming answering investor questions.迈瑞医疗于2024年5月11日召开业绩说明会，董事长李西廷、总经理吴昊、财务负责人赵云、董事会秘书李文楣、独立董事梁沪明回答投资者提问。
2024-05-23Mindray's 8th board 7th meeting resolved to appoint the 2024 auditor, and the 1st extraordinary general meeting was scheduled for June 12, 2024 to vote on the auditor appointment.迈瑞医疗第八届董事会第七次会议审议通过聘任2024年度会计师事务所议案，并定于2024年6月12日召开第一次临时股东大会审议该议案。
2024-07-05Mindray appointed new senior deputy general manager and deputy general manager at the 8th board's 8th meeting.迈瑞医疗第八届董事会第八次会议聘任高级副总经理和副总经理。
2025-05-20Mindray elected Guo Yanmei as employee representative director on the 8th board of directors at the workers' congress.迈瑞医疗职工代表大会选举郭艳美担任第八届董事会职工代表董事。
2025-10-14Mindray's board approved changes to board committee composition: the Nomination Committee will be chaired by Zhou Xianyi, with members Hu Shanrong, Gao Shengping, and Xu Jing; the Strategy and Sustainable Development Committee will add Gu Minkang as a member.迈瑞医疗董事会批准调整董事会专门委员会组成：提名委员会由周先意任主任委员，成员包括胡善荣、高圣平、许静；战略与可持续发展委员会增选顾敏康为成员。
2025-10-14Mindray announced that co-founder Cheng Minghe has stepped down as Vice Chairman, effective from the board resolution date.迈瑞医疗宣布联合创始人成明和不再担任副董事长职务，自董事会决议作出之日起生效。
2026-05-19Mindray held 2025 annual general meeting and 9th board first interim meeting; Li Xiting re-elected as chairman; new senior management team appointed.迈瑞医疗召开2025年度股东大会及第九届董事会第一次临时会议，选举李西廷连任董事长，组建新一届高管团队。
Nanjing and Wuhan base expansion南京与武汉基地扩建
8 · 2024-06-01 → 2025-12-09
▾
Mindray increases investment in Nanjing and opens Wuhan second headquarters迈瑞加大南京投资并启用武汉第二总部
2024-06-01Mindray CEO Liu Laiping met with Nanjing Mayor Chen Zhichang; Mindray plans to increase investment in Nanjing, expand its Nanjing base, and deepen R&D of innovative technologies.迈瑞医疗总裁刘来平会见南京市市长陈之常；迈瑞计划加大在宁投资，扩建南京基地，深化创新技术研发。
2024-07-12Mindray signed a strategic cooperation agreement with Nanjing municipal government to deepen R&D, manufacturing, and industrial ecosystem collaboration.迈瑞医疗与南京市政府签署战略合作协议，深化研发、制造和产业生态合作。
2025-02-11Mindray's Wuhan R&D base in Optics Valley Biolake is under final interior decoration, expected to be fully completed and operational in H1 2025; the global second headquarters base started construction in 2020 and will be put into use this year.迈瑞医疗武汉光谷生物城研发基地正在进行最后室内装修，预计2025年上半年全部完工投入使用；全球第二总部基地2020年开工，今年将投入使用。
2025-05-13Mindray signed a strategic cooperation agreement with Wuhan city to build a second headquarters (Shenzhen + Wuhan dual-core strategy) in Optics Valley, with total investment of RMB 4.5bn, including a super-large R&D center and smart manufacturing base.迈瑞医疗与武汉市签署战略合作协议，投资45亿元在光谷建设第二总部（深圳+武汉双核战略），规划超大型研发中心及智能生产基地。
2025-06-25Wuhan Mindray Bio-Medical Technology Co., Ltd., a wholly-owned subsidiary, increased its registered capital from RMB 500 million to RMB 2 billion, a 300% increase.全资子公司武汉迈瑞生物医疗科技有限公司注册资本由5亿元增至20亿元，增幅300%。
2025-08-03Mindray's global second headquarters, the Wuhan base, officially opened with a total investment of RMB 4.5 billion, covering 620,000 sqm in Wuhan Optics Valley Bio-city, focusing on minimally invasive surgery, orthopedics, and cardiovascular R&D, manufacturing, and training.迈瑞医疗全球第二总部武汉基地正式开园，总投资45亿元，建筑面积62万平方米，位于武汉光谷生物城，专注微创外科、骨科及心血管研发、制造与培训。
2025-12-05Wuhan Mindray Biomedical Technology Co., Ltd. (registered capital 2 billion yuan, wholly owned by Mindray) filed for cancellation due to merger or division.武汉迈瑞生物医疗科技有限公司（注册资本20亿元，迈瑞医疗全资持股）因合并或分立新增注销备案公告。
2025-12-09Mindray completed Series A investment in Wuhan Mindray Technology Co., Ltd. (orthopedic consumables and medical device developer), becoming its controlling shareholder. Wuhan Mindray Biomedical Technology merged into it.迈瑞医疗完成对武汉迈瑞科技（骨科耗材和医疗器械开发企业）的A轮投资，成为其控股股东。武汉迈瑞生物医疗科技有限公司已与其合并。
Shareholder actions & equity股东行动与股权
6 · 2024-06-05 → 2025-09-09
▾
Major shareholder Ever Union reduced stake via block trades; employee stock plan failed to vest.大股东Ever Union通过大宗交易减持；员工持股计划未能解锁。
2024-06-055 block trades of Mindray shares totaling 600 million yuan at a discount price of 300 yuan per share; seller was Huatai Securities Shenzhen Yitian Road Rongchao Business Center, buyers were five different brokerages including CITIC Securities Shanghai Liyang Road.迈瑞医疗出现5笔共计6亿元折价大宗交易，成交价300元/股；卖方为华泰证券深圳益田路荣超商务中心营业部，买方为中信证券上海溧阳路等五家不同营业部。
2025-01-13Controlling shareholders, specific shareholders, employee stock platform, and 2022 ESOP voluntarily pledged not to reduce holdings via secondary market, block trades, or negotiated transfers for 6 months from August 30, 2024.控股股东、特定股东、员工持股平台及2022年员工持股计划自愿承诺：自2024年8月30日起6个月内不减持。
2025-06-29Shareholder Ever Union (H.K.) Limited plans to sell up to 5 million shares (0.41% of total) via block or centralized trading from July 3 to October 2, 2025, citing own capital needs.股东Ever Union (H.K.) Limited计划于2025年7月3日至10月2日通过集中竞价或大宗交易减持不超过500万股（占总股本0.41%），原因为自身资金需求。
2025-07-06Shareholder Ever Union (H.K.) Limited completed a plan to reduce its stake, selling 5 million shares (0.41% of total) via block trades on July 3-4, 2025, at 213.47-213.59 yuan/share, reducing its holding from 4.25% to 3.83%.股东Ever Union（H.K.）Limited于2025年7月3日至4日通过大宗交易累计减持500万股（占总股本0.41%），减持价格213.47-213.59元/股，持股比例从4.25%降至3.83%。
2025-08-28Co-founder Cheng Minghe's Ever Union (H.K.) Limited sold 5 million shares via block trade on July 3-4, 2025, reducing stake by 0.41%.联合创始人成明和旗下Ever Union（H.K.）Limited于2025年7月3-4日通过大宗交易减持500万股，减持比例0.41%。
2025-09-09Founder reduced holdings by 5 million shares in July 2025, netting 1.113 billion yuan; employee stock ownership plan failed to unlock due to unmet 2024 performance targets, resulting in about 150 million yuan in lost potential gains.创始人2025年7月减持500万股获利11.13亿元；因2024年业绩未达标，员工持股计划无法解锁，错失约1.5亿元潜在收益。
AED product launches and recallAED产品发布与召回
3 · 2024-06-21 → 2024-12-04
▾
Mindray launches new AED series and initiates voluntary recall of defibrillators迈瑞发布新AED系列并对除颤仪发起主动召回
2024-06-21Mindray initiated a voluntary Class II recall of 4,483 units of semi-automatic and automatic external defibrillators (BeneHeart C, BeneHeart S series) due to potential incorrect function configuration; no reports of death or serious injury.迈瑞医疗主动召回4483台半自动和自动体外除颤器（BeneHeart C、BeneHeart S系列），因可能存在功能配置不正确，召回级别为二级；未收到死亡或严重伤害报告。
2024-09-27Mindray launched new-generation AED BeneHeart E/L series, featuring smallest volume at same energy, 7-second shock delivery, and IoT-enabled CPR quality monitoring.迈瑞医疗推出全新一代AED BeneHeart E/L系列，同等能量下体积最小、从开机到放电仅7秒，集成物联网实现高质量心肺复苏。
2024-12-04Mindray launched a new generation of AEDs featuring ResQNavi intelligent急救 navigation technology, which automatically adjusts voice and animation prompts based on the rescuer's proficiency.迈瑞医疗推出新一代AED，搭载ResQNavi®智能急救导航技术，可根据施救者熟练程度自动调整语音和动画提示。
International expansion & globalization国际化与全球化
17 · 2024-06-27 → 2026-03-02
▾
Mindray reported strong international revenue growth, expanding overseas subsidiaries and partnerships.迈瑞国际收入增长强劲，拓展海外子公司和合作伙伴关系。
2024-06-27Mindray's 2023 overseas revenue reached 13.549 billion yuan, up 15.83% year-on-year, accounting for 38.79% of total revenue of 34.93 billion yuan, ranking first among Chinese medical device companies in overseas revenue.迈瑞医疗2023年境外收入达135.49亿元，同比增长15.83%，占总营收349.3亿元的38.79%，在中国医疗器械企业中境外收入规模位列第一。
2024-08-29Mindray's 2024 half-year report showed overseas market revenue of 7.906 billion yuan, up 18% YoY, with international strategic clients contributing 14% of international sales.迈瑞医疗2024半年报显示海外市场营收79.06亿元，同比增长18%，国际战略客户贡献占国际市场销售比例达14%。
2024-09-17Mindray stated at performance briefing that it expects overseas markets, especially developing countries and Europe, to maintain rapid growth; aims to enter global medical device TOP20 by 2025 at the latest.迈瑞医疗在业绩说明会上表示预计海外市场（尤其是发展中国家和欧洲）保持快速增长，最晚2025年进入全球医疗器械TOP20。
2024-10-29Mindray's international market revenue grew over 18% in 9M 2024, with Europe and Asia-Pacific each growing over 30%, driven by high-end strategic customers and seed businesses (animal health, minimally invasive surgery, AED).迈瑞医疗国际市场前三季度收入增长超18%，欧洲和亚太市场均增长超30%，受益于高端战略客户和种子业务（动物医疗、微创外科、AED）放量。
2024-11-01International market revenue grew nearly 19% in Q3, with developing countries >20% and Europe nearly 30%. Non-US high-end strategic customer revenue grew >60% in the first three quarters. International IVD grew >30%, international minimally invasive surgery and AED each grew >50%, and international animal medical grew >30%.第三季度国际市场收入增长近19%，其中发展中国家增长超20%，欧洲增长近30%。除美国外的高端战略客户前三季度收入增长超60%。国际IVD增长超30%，国际微创外科和AED增速均超50%，国际动物医疗增速超30%。
2025-01-19Board Secretary Li Wenmei identified three medium-to-long-term growth pillars: digital-intelligent innovation, consumables business expansion, and accelerated globalization; supply chain localization underway in over 10 overseas countries starting with consumables.董秘李文楣提出三大中长期增长支柱：数智化创新、拓展耗材业务、加速全球化；海外10多个国家供应链本地化已启动，从耗材业务开始。
2025-04-28Mindray's international business revenue in FY2024 reached RMB 16.434 billion (+21.28% YoY), accounting for 44.75% of total revenue; developing countries contributed RMB 10.91 billion (+24.59% YoY).迈瑞医疗2024年国际业务收入164.34亿元（同比+21.28%），占总收入44.75%；发展中国家贡献109.10亿元（同比+24.59%）。
2025-05-01Mindray's international revenue in 2024 reached RMB 16.434bn (+21.28% YoY), accounting for 44.75% of total revenue; developing countries contributed RMB 10.91bn (+24.59% YoY), 29.71% of total revenue.迈瑞医疗2024年国际业务收入164.34亿元（同比+21.28%），占总收入44.75%；发展中国家收入109.1亿元（同比+24.59%），占总收入29.71%。
2025-07-02Mindray's international revenue grew 21.28% in 2024, accounting for 44.75% of total revenue; developing countries contributed 66.39% of international revenue.迈瑞医疗2024年国际业务收入增长21.28%，占总收入比重44.75%；发展中国家贡献国际收入的66.39%。
2025-07-07Mindray stated its long-term goal to raise international revenue share to 70% and is actively expanding overseas local platforms.迈瑞医疗表示长期目标将国际营收占比提升至70%，并积极建设海外本地化平台。
2025-08-27International business revenue reached RMB 8.332 billion in H1 2025, accounting for 50% of total revenue, up 5.39% YoY; developing countries grew 6% to RMB 5.435 billion.2025年上半年国际业务收入83.32亿元，占总营收50%，同比增长5.39%；发展中国家收入54.35亿元，同比增长6%。
2025-09-01In H1 2025, Mindray's international revenue reached 8.332 billion yuan, accounting for 50% of total revenue for the first time; IVD revenue was 6.424 billion yuan, with international IVD growing double digits and international chemiluminescence growing over 20%.2025年上半年，迈瑞医疗国际业务收入达83.32亿元，占整体营收比重首次达到50%；体外诊断业务实现营收64.24亿元，其中国际体外诊断业务同比实现双位数增长，国际化学发光业务增长超过20%。
2025-11-06Mindray stated that developing countries are the core growth engine for international business. In Q3 2025, the Middle East, Africa and CIS region grew 18%, India grew 15%, and overall developing country growth accelerated.迈瑞医疗表示发展中国家是国际业务核心增长引擎。2025年第三季度，中东非和独联体地区增长18%，印度增长15%，整体发展中国家增长明显提速。
2025-12-18Mindray disclosed that international business accounted for over half of total revenue in the first three quarters of 2025, and expects the share to keep rising, especially in developing countries.迈瑞医疗披露2025年前三季度国际业务占整体收入比重已超过一半，预计未来几年国际收入占比将持续提升，尤其发展中国家将维持快速增长。
2026-01-06Mindray stated that international business accounted for over half of total revenue in the first three quarters of 2025, and expects the share to keep rising in coming years.迈瑞表示2025年前三季度国际业务占整体收入比重已超过一半，预计未来几年国际收入占比将持续提升。
2026-01-18At the 44th J.P. Morgan Healthcare Conference, Mindray outlined a 10-year growth blueprint with three pillars: accelerating globalization, expanding recurring business, and digital transformation. It operates 64 subsidiaries, 5 R&D centers, and 14 production bases across 40+ countries.在第44届摩根大通医疗健康大会上，迈瑞提出未来十年增长蓝图，三大支柱为加速全球化、流水业务拓展和数智化转型；已在40多个国家设有64家子公司、5个研发中心和14个生产基地。
2026-03-02Mindray stated that its products cover over 190 countries and regions; overseas revenue accounted for about 50% of total revenue in H1 2025, with North America contributing about 8%; the company is monitoring tariff policy changes.迈瑞医疗表示，产品覆盖全球190多个国家和地区；2025年上半年海外收入约占总收入的50%，其中北美地区约占8%；公司正密切关注关税政策变化。
ESG and sustainabilityESG与可持续发展
5 · 2024-07-19 → 2026-05-29
▾
Mindray receives ESG ratings, joins UN Global Compact, and publishes sustainability report迈瑞获得ESG评级、加入联合国全球契约并发布可持续发展报告
2024-07-19Mindray was first included in S&P Global's 'Sustainability Yearbook (China Edition) 2024', with MSCI ESG rating upgraded to AA and CDP climate rating to B.迈瑞医疗首次入选标普全球《可持续发展年鉴（中国版）2024》，MSCI ESG评级升至AA级，CDP气候评级升至B级。
2025-04-29Mindray published its 2024 Sustainability Report, announcing its formal joining of the UN Global Compact.迈瑞医疗发布2024年可持续发展报告，宣布正式加入联合国全球契约。
2025-06-30Mindray maintained an MSCI ESG rating of AA for the third consecutive year, ranking among global leaders in the healthcare equipment & supplies industry; carbon intensity in 2024 fell 11.6% vs 2021.迈瑞连续第三年保持MSCI ESG评级AA级，处于医疗保健设备与用品行业全球领先者之列；2024年碳排放强度较2021年下降11.6%。
2026-05-22Mindray was selected for the third consecutive year in S&P Global's 'Sustainability Yearbook (China Edition) 2026', ranking first in the healthcare equipment and supplies industry.迈瑞医疗连续第三年入选标普全球《可持续发展年鉴（中国版）2026》，位列医疗保健设备与耗材行业第一。
2026-05-29Mindray was selected as one of nine listed companies in the first batch of the Shenzhen Stock Exchange's 'ESG Practice English Case Collection'.迈瑞医疗入选深交所首批《深市上市公司ESG实践英文案例集》九家上市公司之一。
Financial reporting & guidance财报与业绩指引
16 · 2024-07-25 → 2026-04-30
▾
Mindray announced financial report release dates, provided revenue guidance, and disclosed performance trends.迈瑞公布财报发布日期，提供业绩指引，并披露业绩趋势。
2024-07-25Mindray announced it will release its 2024 semi-annual report on August 30.迈瑞医疗宣布将于8月30日公布2024年半年报。
2025-01-10Company states operations are normal; 2024 annual report will be published on April 29, 2025.公司表示生产经营一切正常；2024年年报将于2025年4月29日公布。
2025-04-23Mindray announced it will publish its 2024 annual report on April 29, 2025.迈瑞医疗宣布将于2025年4月29日公布2024年年报。
2025-04-28Mindray guided that domestic business will see a major inflection point from Q3 2025, with revenue expected to follow a 'low first half, high second half' pattern and improve quarter by quarter.迈瑞医疗指引国内业务将从2025年三季度起迎来重大拐点，预计收入呈“前低后高”分布并逐季改善。
2025-05-01Mindray's domestic revenue in 2024 fell 5.10% YoY due to weak hospital equipment procurement; 2025Q1 domestic revenue declined over 20% YoY.迈瑞医疗2024年国内收入同比下降5.10%，因医院设备采购疲软；2025年一季度国内收入同比下降超20%。
2025-06-27Mindray's 2024 net profit growth slowed to 0.74%, the lowest since A-share listing, causing the third tranche of the 2022 employee stock ownership plan to fail vesting (target was 73% growth from 2021 base). Domestic market revenue fell 5.1% in 2024.迈瑞2024年归母净利润增速降至0.74%，创A股上市以来新低，导致2022年员工持股计划第三期解锁失败（目标为较2021年增长73%）。2024年国内市场收入下降5.1%。
2025-07-02Mindray expects a major inflection point in overall revenue YoY growth in Q3 2025.迈瑞医疗预计整体营收同比增速的重大拐点将在2025年第三季度显现。
2025-08-27Guided Q3 2025 revenue to achieve positive YoY growth and sequential quarterly improvement; international IVD line expected to grow rapidly.预计2025年第三季度营业收入同比正增长，并延续逐季环比改善趋势；国际体外诊断产线有望较快增长。
2025-09-08Mindray's domestic business in H1 2025 declined over 30% YoY, reflecting the lagged impact of 2024 tender declines and extended revenue recognition cycles.迈瑞医疗2025年上半年国内业务同比下滑超过30%，反映2024年招标下滑的滞后影响及收入确认周期拉长。
2025-10-14Mindray guided that Q3 2025 consolidated revenue will return to positive year-on-year growth, with international revenue growth accelerating and domestic market improving, marking a performance inflection point.迈瑞医疗预计2025年第三季度整体营业收入将实现同比正增长，国际市场增长提速，国内市场改善，迎来业绩拐点。
2025-10-30Mindray stated in its Q3 earnings call that its international business grew 12% YoY in Q3, with Europe up over 20% and CIS/Middle East/Africa achieving double-digit growth. The company expects Q4 revenue growth to accelerate vs Q3.迈瑞医疗在三季度业绩说明会上表示，第三季度国际业务同比增长12%，其中欧洲市场增长超20%，独联体及中东非地区实现双位数增长，预计第四季度营收增速较第三季度有所提升。
2025-11-10Mindray guided that Q4 2025 revenue YoY growth will accelerate vs Q3. Q3 2025 revenue was RMB 9.09 billion, +1.5% YoY, +6.9% QoQ.迈瑞医疗预计2025年第四季度营业收入同比增长较第三季度将有所提速。第三季度营收90.9亿元，同比增长1.5%，环比增长6.9%。
2026-03-10Mindray announced it will release its 2025 annual report on 2026-03-31.迈瑞医疗宣布将于2026年3月31日发布2025年年度报告。
2026-03-30Mindray's 2025 annual report showed international revenue of 17.650 billion yuan, up 7.40% YoY, accounting for 53% of total revenue; emerging business (newly reported separately) revenue of 5.378 billion yuan, up 38.85% YoY, representing 16% of total revenue.迈瑞医疗2025年年报显示，国际业务收入176.50亿元，同比增长7.40%，占总营收53%；新兴业务（首次单独列示）收入53.78亿元，同比增长38.85%，占总营收16%。
2026-04-01Mindray's 2025 net profit margin fell 6.57 ppts, mainly due to a 2.80 ppt decline in gross margin from domestic price cuts, increased international market spending, higher R&D expense ratio, and forex losses.迈瑞医疗2025年净利润率下降6.57个百分点，主要因国内产品降价导致毛利率下降2.80个百分点，以及加大国际市场投入、研发费用率提升和汇兑损失。
2026-04-30Mindray disclosed that its Q1 2026 contract liabilities reached RMB 3.342 billion, up 50.18% YoY, indicating strong future revenue visibility.迈瑞医疗披露2026年一季度末合同负债达33.42亿元，同比高增50.18%，预示未来收入强劲。
Investor relations & clarifications投资者关系与澄清
8 · 2024-07-25 → 2026-06-05
▾
Mindray responded to investor inquiries, denying involvement in BCI, peritoneal dialysis, and Huawei cooperation.迈瑞回应投资者询问，否认涉足脑机接口、腹膜透析和华为合作。
2024-07-25Mindray confirmed it does not currently engage in brain-computer interface related business.迈瑞医疗确认目前不涉及脑机接口相关业务。
2025-02-12Mindray stated it has no involvement in brain-computer interface (BCI) business, responding to investor inquiry.迈瑞医疗回应投资者提问，表示目前未涉及脑机接口业务。
2025-02-12Mindray stated it has no involvement in automated peritoneal dialysis machine business, responding to investor inquiry.迈瑞医疗回应投资者提问，表示目前未涉及自动腹膜透析机业务。
2025-03-12Mindray stated in an investor interaction that it currently has no cooperation with Huawei.迈瑞医疗在投资者互动中表示，公司目前不涉及与华为的合作。
2025-12-18Mindray stated in an investor Q&A that it has no involvement in brain-computer interface technology.迈瑞医疗在投资者互动平台表示，公司目前没有涉及脑机接口技术业务。
2026-05-21Mindray denied forcing dealers to stockpile inventory, stating procurement is based on end demand and dealer inventory decisions.迈瑞医疗否认向经销商强制压货，称采购基于终端需求与经销商库存决策。
2026-06-01Multiple distributors accused Mindray of强制压货, causing inventory losses of millions of yuan; Mindray denied强制压货 but did not address buyback mechanism.多位经销商炮轰迈瑞医疗强制压货导致百万元级亏损；迈瑞医疗否认强制压货，但未回应库存回购机制。
2026-06-05Mindray denied any change in actual controller amid market cap decline, stating operations are normal.迈瑞医疗否认实际控制人发生变化，表示公司生产经营一切正常。
Overseas production bases海外生产基地
5 · 2024-07-30 → 2025-11-06
▾
Mindray activates localized production bases in multiple overseas countries迈瑞在多个海外国家启动本地化生产基地
2024-07-30Mindray plans to activate over 10 overseas localized production bases including Mexico by end of 2024 to mitigate tariff risks.迈瑞医疗计划到2024年底启用包括墨西哥在内的10个以上海外本地化生产基地，以应对关税风险。
2024-10-30Mindray stated at the performance briefing that it plans to start localized production in 13 overseas countries in 2025-2026, gradually introducing more products.迈瑞医疗在业绩说明会上表示，计划明后两年在海外13个国家启动本地化生产，并逐步导入更多产品。
2025-05-01Mindray has set up localized production projects in 13 countries globally, with 9 already in production.迈瑞医疗已在全球13个国家布局本地化生产项目，其中9个国家已开启生产。
2025-09-01Mindray expanded overseas IVD local platform capabilities in manufacturing, logistics, clinical support, and IT services.迈瑞医疗持续加码国际体外诊断业务的生产制造、物流配送、临床支持、IT服务等本地化平台建设。
2025-11-06Mindray disclosed that it has planned localized production projects in 14 overseas countries, with 11 already launched. The total addressable market for its existing businesses internationally is about RMB 570 billion; 2024 international revenue was ~RMB 16.4 billion, representing low single-digit market share.迈瑞医疗披露已在海外14个国家规划本地化生产项目，其中11个国家已启动。公司已布局业务的国际可及市场约5700亿元，2024年国际收入约164亿元，市占率仅为低个位数。
Seed businesses & new segments种子业务与新领域
7 · 2024-07-30 → 2026-05-28
▾
Mindray cultivated minimally invasive surgery, cardiovascular, animal medical, and surgical robot businesses.迈瑞培育微创外科、心血管、动物医疗和手术机器人业务。
2024-07-30Mindray disclosed that its minimally invasive surgery seed business grew over 30% in 2023, and it will explore surgical robotics business.迈瑞医疗披露2023年微创外科种子业务增长超30%，并将探索手术机器人业务。
2024-09-03Mindray completed product layout for thoracic and abdominal minimally invasive surgery, including 4K+fluorescence and 4K+3D laparoscopy systems, electrosurgical knife, ultrasonic scalpel, energy platform, and staplers; stapler success rate >98%, matching imported brands.迈瑞医疗完成胸腹腔微创外科手术产品布局，包括4K+荧光和4K+3D胸腹腔硬镜系统、电刀、超声刀、能量平台、腔镜吻合器等；吻合器成钉良率超过98%，与进口品牌一致。
2025-07-07Mindray plans to cultivate seed businesses including minimally invasive surgery, cardiovascular, and animal medical, which together contributed 12% of 2024 revenue; it is exploring molecular diagnostics, clinical mass spectrometry, and surgical robots.迈瑞医疗计划重点培育微创外科、心血管、动物医疗等种子业务，2024年三者合计收入占比12%；并探索分子诊断、临床质谱、手术机器人等新兴赛道。
2025-09-03Mindray completed foundational capability layout in laparoscopy, energy platforms, and instruments, preparing to enter the surgical robot赛道.迈瑞医疗在腔镜、能量平台与器械等基础领域完成底层能力布局，为切入手术机器人赛道做好准备。
2026-04-09Through MPI process management, HuiTai Medical's 3D atrial fibrillation PFA and RFA systems and consumables received NMPA approval, entering the high-barrier atrial fibrillation field in 2025.在迈瑞MPI流程管理下，惠泰医疗的三维房颤PFA、RFA系统及配套耗材已通过NMPA批准，2025年正式进军房颤领域。
2026-04-09Mindray plans to integrate endoscopy, energy platform, and surgical instruments to accelerate the launch of surgical robots for various specialties.迈瑞医疗计划融合腔镜、能量平台和手术器械，加快推出各个专科的手术机器人产品。
2026-05-28Mindray stated that its orthopedics business achieved high growth for two consecutive years; overseas revenue accounted for 40% of orthopedics revenue in 2025.迈瑞医疗表示骨科业务已连续两年高增长，2025年海外收入占骨科收入比例达四成。
Market share & competitive positioning市场份额与竞争定位
6 · 2024-07-30 → 2025-10-30
▾
Mindray disclosed domestic market share gains in chemiluminescence and IVD, and price war concerns.迈瑞披露在化学发光和IVD领域的国内市场份额提升，以及价格战担忧。
2024-07-30Mindray stated its chemiluminescence business domestic market share is expected to surpass another imported brand, and next-gen high-end chemiluminescence instrument R&D is progressing smoothly.迈瑞医疗表示化学发光业务国内市占率有望再超一家进口品牌，下一代高端化学发光仪器研发进展顺利。
2024-08-01Mindray disclosed that its chemiluminescence business domestic market share is expected to surpass another imported brand, and the next-generation high-end chemiluminescence instrument R&D is progressing smoothly.迈瑞医疗披露其化学发光业务国内市占率有望再超一家进口品牌，且下一代高端化学发光仪器研发进展顺利。
2024-12-31Mindray expects to install over 150 sets of 'full-laboratory large-scale automated lines' in China in 2024, mostly in tertiary hospitals, with installations expected to hit a new high in 2025.迈瑞医疗预计2024年国内将实现150套以上'全实验室大型自动化流水线'装机，大部分在三级医院，2025年装机数量有望创新高。
2025-09-03Mindray won a bid at under 1,000 yuan, sparking price war concerns and potential conflict with NMPA's anti-involution policy from July 24.迈瑞医疗以不足千元价格中标，引发价格战担忧，或与国家医保局7月24日倡导的反内卷政策存在背离。
2025-09-09Mindray clarified that MT 8000 full-lab intelligent流水线 sold 13 units internationally and received 185 new orders domestically in H1 2025.迈瑞医疗澄清，MT 8000全实验室智能化流水线2025年上半年在国际市场销售13套，在国内市场新增订单185套。
2025-10-30Mindray's senior VP Li Zaiwen stated that the company aims to increase its domestic market share in chemiluminescence, biochemistry, and coagulation from 10% to 20% over the next three years, driven by import substitution.迈瑞医疗高级副总裁李在文表示，在国产替代趋势下，未来三年公司在化学发光、生化、凝血等领域的国内市场占有率有望从10%提高至20%。
Patent lawsuits and IP disputes专利诉讼与知识产权纠纷
3 · 2024-08-01 → 2026-03-24
▾
Mindray settles IP dispute with Biolight and faces patent lawsuits with Comen and Teratech迈瑞与宝莱特和解知识产权纠纷，并与科曼、Teratech发生专利诉讼
2024-08-01Mindray and Biolight reached a comprehensive settlement on intellectual property disputes, with an impact of approximately 2 million yuan on Biolight's current profit.迈瑞医疗与宝莱特就知识产权纠纷达成全面和解，对宝莱特本期利润影响金额约为200万元。
2024-09-23Mindray's 10-year patent infringement lawsuit against Comen Medical (Shenzhen) over ventilator patents resurfaced; Mindray's ventilator market share fell from 35.87% (2022) to 31.91% (2023).迈瑞医疗与科曼医疗长达10年的呼吸机专利侵权诉讼再度受关注；迈瑞呼吸机市占率从2022年35.87%降至2023年31.91%。
2026-03-24Mindray confirmed it is involved in a patent lawsuit with US-based Teratech (Terason) (Case No. 1:25-cv-01149-mn); the company filed a motion to dismiss in December 2025, with a court ruling expected in 2026; Mindray asserts non-infringement and patent invalidity to protect US sales.迈瑞医疗确认与美国Teratech（Terason）存在专利诉讼（案号1:25-cv-01149-mn）；公司已于2025年12月发起驳回起诉动议，预计2026年法院裁决；迈瑞主张不侵权和专利无效以保护美国产品销售。
University and hospital partnerships大学与医院合作
4 · 2024-08-09 → 2025-03-18
▾
Mindray signs strategic agreements with universities and hospitals for innovation迈瑞与大学及医院签署战略合作协议推动创新
2024-08-09Mindray signed a strategic cooperation agreement with the School of Medicine of The Chinese University of Hong Kong, Shenzhen, to jointly build a first-class medical service hub in the Greater Bay Area.迈瑞医疗与香港中文大学（深圳）医学院签署战略合作协议，立足深圳和大湾区打造国际一流医疗服务新高地。
2024-09-25Mindray signed a comprehensive strategic cooperation agreement with Fudan University Affiliated Pediatric Hospital to jointly advance pediatric healthcare innovation and smart medical solutions.迈瑞医疗与复旦大学附属儿科医院签署全面战略合作协议，共同推动儿童健康事业和智慧医疗发展。
2025-01-27Shenzhen Health Development Research and Data Management Center signed a strategic cooperation agreement with Mindray to collaborate on medical IoT, AI, 5G, cloud computing, big data, and talent development.深圳市卫生健康发展研究和数据管理中心与迈瑞医疗签署战略合作协议，合作领域包括医疗物联网、人工智能、5G、云计算、大数据及人才培养。
2025-03-18Mindray signed a cooperation agreement with International Medical (Xi'an International Medical), focusing on AI medical applications, clinical decision support system optimization, scientific innovation, international medical resource sharing, and centralized procurement of medical equipment, to build a 'Mindray + International Medical' AI medical benchmark.迈瑞医疗与国际医学（西安国际医学）签署合作协议，围绕AI医疗应用、临床辅助决策系统优化、科技创新、国际医疗资源共享及医疗设备集约化采购等核心议题，打造“迈瑞+国际医学”AI医疗标杆。
Product launches & innovation产品发布与创新
8 · 2024-08-28 → 2026-06-01
▾
Mindray launched new ultrasound, IVD, and surgical products, including AI-powered and premium devices.迈瑞推出新的超声、IVD和外科产品，包括AI驱动的和高端设备。
2024-08-28Mindray showcased its medical imaging solutions at a conference, including Kunlun Resona A20, Kunpeng Recho R9, Kunlun Resona I9, and Ruiyingyun++ 5G smart terminal Lingke, and reiterated its 'Project 2025' initiative for ultrasound.迈瑞医疗在会议上展示了医学影像产品解决方案，包括昆仑Resona A20、鲲鹏Recho R9、昆仑Resona I9、瑞影云++5G智能终端-灵珂，并重申了超声领域的“2025行动”倡议。
2024-09-24Mindray exhibited multiple digital-intelligent products at 2024 CIFTIS, including ultra-high-end ultrasound platform Resona A20 (first commercial device achieving super-resolution blood flow imaging).迈瑞医疗在2024年服贸会展出多款数智化产品，包括超高端超声平台Resona A20（业内首款商用超分辨率血流成像设备）。
2024-12-17Mindray showcased its new generation obstetrics and gynecology ultrasound solution, the Nuewa A20, at the 24th Chinese Medical Association Ultrasound Medical Conference (CSUM2024) in Wuhan.迈瑞医疗在中华医学会第二十四次超声医学学术会议（CSUM2024）上展出新一代妇产超声解决方案——女娲Nuewa A20。
2025-03-05Mindray obtained the domestic AI medical device certificate for prenatal ultrasound (approval number: Yue Medical Device Registration 20242060970) in July 2024, and launched the ultra-high-end obstetrics and gynecology ultrasound Nuewa A20, which integrates AI with a full-stack panoramic intelligent ultrasound solution.迈瑞医疗于2024年7月获得国产产前超声人工智能医疗器械证（批号：粤械注准20242060970），并推出深度融合AI技术的超高端妇产超声女娲Nuewa A20，搭载全栈全景智能超声解决方案。
2025-09-05Mindray received NMPA registration for its Alpha-fetoprotein (AFP) assay kit (chemiluminescence immunoassay), registration number 20253401791.迈瑞医疗的甲胎蛋白（AFP）测定试剂盒（化学发光免疫分析法）获得国家药监局注册，注册证编号为国械注准20253401791。
2025-12-01Mindray established a new ultrasound business unit, led by Lin Feng (former GE Healthcare executive), focusing on self-developed core components (probes, hosts, boards) for cardiac, obstetrics, and interventional scenarios.迈瑞医疗成立超声新事业部，由前GE医疗高管林峰负责，聚焦心脏、妇产、介入等场景的核心部件（探头、主机、板卡）自研。
2025-12-05Mindray showcased ultra-premium general ultrasound Resona A20 (first clinical ultra-resolution blood flow imaging) and other innovations at RSNA 2025 in Chicago, marking entry into North American premium ultrasound market.迈瑞医疗在芝加哥RSNA 2025上展出超高端全身应用超声Resona A20（首款临床超分辨率血流成像）等创新产品，标志着超声业务进入北美高端市场。
2026-06-01Mindray launched CX-3000 and CX-2000 fully automatic coagulation analyzers for the primary care market, extending reagent open-vial stability to over 30 days.迈瑞医疗面向基础医疗市场推出CX-3000、CX-2000全自动凝血分析仪，将试剂开瓶有效期延长至30天以上。
Digital transformation and ecosystem数字化转型与生态系统
2 · 2024-09-01 → 2024-10-12
▾
Mindray builds 'Equipment + IT + AI' ecosystem with Sanrui solutions迈瑞构建“设备+IT+AI”生态系统，推出三瑞解决方案
2024-09-01Mindray's 'Sanrui' digital ecosystem (RuiZhiLian, RuiYingYun++, Mindray ZhiJian) cumulative sales plus driven equipment sales reached ~4.5B yuan over past 3 years.迈瑞医疗“三瑞”数智化方案（瑞智联、瑞影云++、迈瑞智检）过去三年累计销售额及带动的设备销售额共计约45亿元。
2024-10-12Mindray was added to the 'Smart Healthcare' concept index; it has built an 'Equipment + IT + AI' smart medical ecosystem via the 'Sanrui' (Three-Rui) solutions.迈瑞医疗新增'智能医疗'概念；通过'三瑞'解决方案构建了'设备+IT+AI'智能医疗生态系统。
Government & leadership meetings政府与领导会晤
4 · 2024-09-04 → 2025-07-08
▾
Mindray executives met with Chinese provincial and national leaders to discuss investment and policy support.迈瑞高管与中国省级和国家领导人会晤，讨论投资和政策支持。
2024-09-04Henan Provincial Party Secretary An Wei led a delegation to Shenzhen and held talks with Mindray President Liu Laiping on expanding cooperation and accelerating project construction.河南省委书记安伟带队赴深圳与迈瑞医疗行政总裁刘来平会谈，围绕拓展合作、加快项目建设达成共识。
2024-11-13Shenzhen Mayor Liu Xiaotao met with Mindray Chairman Li Xiting. Li expressed willingness to deepen cooperation with Suzhou, focusing on 'AI + healthcare' to promote technology innovation and expand application scenarios.深圳市市委书记刘小涛会见迈瑞医疗董事长李西廷。李西廷表示希望与苏州深化合作，聚焦“人工智能+医疗”领域，推动技术创新和拓展应用场景。
2025-02-10Mindray chairman Li Xiting met with Hubei provincial party secretary and governor in Wuhan to discuss expanding investment and cooperation in Hubei, focusing on high-end medical equipment and life health industry.迈瑞医疗董事长李西廷在武汉与湖北省委书记、省长座谈，讨论扩大在鄂投资合作，聚焦高端医疗装备和生命健康产业。
2025-07-08Chinese Vice Premier Liu Guozhong visited Mindray during a Guangdong inspection on July 3-5, 2025, praising its innovation and encouraging R&D in high-end medical devices and AI.国务院副总理刘国中于2025年7月3日至5日赴广东调研期间走访迈瑞医疗，肯定其创新并鼓励高端医疗器械和AI研发。
New subsidiaries and capital increases新子公司与增资
3 · 2024-09-24 → 2026-01-04
▾
Mindray establishes new subsidiaries in Nanchang, Jinan and increases Wuhan subsidiary capital迈瑞在南昌、济南设立新子公司并增加武汉子公司注册资本
2024-09-24Mindray established a wholly-owned subsidiary Nanchang Mindray Electronic Technology Co., Ltd. with registered capital of 5M yuan, engaged in medical device manufacturing.迈瑞医疗在南昌成立全资子公司南昌迈瑞电子科技有限公司，注册资本500万元，从事医疗器械生产。
2024-10-08Mindray established a wholly-owned subsidiary Nanchang Mindray Electronic Technology Co., Ltd. with registered capital of 5 million yuan, covering Class I/II/III medical device production.迈瑞医疗成立全资子公司南昌迈瑞电子科技有限公司，注册资本500万元，经营范围涵盖第一、二、三类医疗器械生产。
2026-01-04Mindray established a wholly-owned subsidiary, Jinan Mindray Technology Co., Ltd., with a registered capital of 20 million RMB, covering instrument manufacturing and Class I medical device production.迈瑞医疗全资设立济南迈瑞科技有限公司，注册资本2000万元，经营范围涵盖仪器仪表制造和第一类医疗器械生产。
Strategic partnerships & MoUs战略合作与备忘录
5 · 2024-10-25 → 2026-03-04
▾
Mindray signed cooperation agreements with BOE, BD, and other firms for technology and market expansion.迈瑞与京东方、BD等公司签署合作协议，拓展技术和市场。
2024-10-25Mindray signed a strategic cooperation agreement with Zhejiang Dongri New Technology Development Co., Ltd. (subsidiary of Zhejiang Dongri, 600113) to collaborate on medical system integration and hospital supply chain management across its three main product lines.迈瑞医疗与浙江东日（600113）全资子公司浙江东日新技术发展有限公司签署战略合作协议，在三大产线领域合作医疗系统集成和医院供应链管理。
2024-10-28Mindray co-hosted the '2024 Mindray-Jianfa Zhixin Provincial Channel Conference' in Kunming, Yunnan, focusing on IVD products and market expansion.迈瑞医疗与建发致新在云南昆明联合主办'2024迈瑞医疗建发致新省级渠道会'，聚焦体外诊断产品和市场拓展。
2025-12-29Mindray signed a strategic cooperation agreement with BOE to collaborate on displays, smart hospitals, medical sensors, IVD, and industrial internet, unveiling portable ultrasound, 24-inch monitor VMAX, and DR flat-panel detector.迈瑞医疗与京东方签署战略合作协议，围绕显示器件、智慧医院、医疗传感、体外诊断、工业互联网等领域合作，并发布便携超声、24英寸监护VMAX显示终端及DR平板探测器。
2026-01-22Mindray North America and Medtronic expanded their patient monitoring partnership from hospitals to U.S. Ambulatory Surgery Centers (ASC), integrating Medtronic's next-gen INVOS 7100 regional oximetry and new BIS brain monitoring systems.迈瑞北美与美敦力将患者监护合作从医院扩展至美国门诊手术中心，集成美敦力下一代INVOS 7100区域血氧监测系统和新一代BIS脑功能监测系统。
2026-03-04Mindray's IVD division and BD Biosciences announced a strategic partnership focusing on clinical flow cytometry, covering channel cooperation, technology integration, and brand collaboration to advance smart diagnostics.迈瑞医疗体外诊断事业部与碧迪医疗生物科学宣布达成战略合作，聚焦临床流式领域，开展渠道合作、技术整合和品牌协作，推动智慧检验发展。
Animal medical business动物医疗业务
5 · 2024-10-30 → 2026-06-02
▾
Mindray expands animal medical business globally with dedicated subsidiary迈瑞通过专门子公司全球拓展动物医疗业务
2024-10-30Mindray's animal health business has expanded to cover over 100 countries and regions, with products spanning medical imaging, IVD, and life information & support for animals.迈瑞动物医疗业务已覆盖全球100多个国家和地区，产品涵盖动物用医学影像、体外诊断、生命信息与支持三大领域。
2024-12-09Mindray established a dedicated animal medical subsidiary in 2020, leveraging its human medical technology synergies to accelerate new product development in the animal health field.迈瑞医疗于2020年成立动物医疗子公司，利用人用技术协同效应加速动物医疗领域新产品开发。
2025-06-04Mindray confirmed on investor platform that it is actively strengthening its layout in the pet medical market, citing rising pet ownership and consumption driven by aging population and declining birth rates.迈瑞医疗在投资者平台确认正积极加强宠物医疗市场布局，指出受人口老龄化和生育率下降驱动的宠物拥有量和消费增长。
2025-11-06Mindray stated animal medical business is a high-potential segment; it has completed product lines for three major segments and formed a full digital-intelligent solution, driving overseas high-end pet hospital breakthroughs. International revenue accounted for over 80% of animal medical revenue in H1 2025.迈瑞医疗表示动物医疗是高潜力业务，已补齐三大产线产品，形成完整数智化解决方案，带动海外高端宠物医院突破。2025年上半年动物医疗国际收入占比超过80%。
2026-06-02Mindray Animal Medical received CNAS National Accredited Laboratory and Guangdong Provincial Industrial Design Center certifications.迈瑞动物医疗获得CNAS国家认可实验室与广东省工业设计中心两项资质认证。
Awards & certifications奖项与认证
2 · 2024-12-05 → 2025-07-16
▾
Mindray obtained ISO 56005 Level 4 certificate and EU MDR certificates for surgical instruments.迈瑞获得ISO 56005四级证书和外科器械的欧盟MDR证书。
2024-12-05Mindray obtained ISO 56005 Innovation and Intellectual Property Management Capability Level 4 certificate, becoming the first medical device company in China to achieve this highest level.迈瑞医疗获得ISO 56005《创新与知识产权管理能力》四级证书，成为全国医疗器械领域首家达到此最高级别的企业。
2025-07-16TÜV Rheinland issued EU MDR certificates for Mindray's staplers, ligation clips, and reusable high-frequency surgical instruments, confirming compliance with EU regulations.TÜV莱茵为迈瑞医疗的吻合器、结扎夹及复用高频手术器械三大核心外科产品线颁发欧盟MDR公告机构证书。
Manufacturing & supply chain制造与供应链
4 · 2024-12-09 → 2026-01-26
▾
Mindray advanced its Dangshan base construction and digital supply chain, and closed IPO-funded projects.迈瑞推进砀山基地建设和数字供应链，并关闭IPO募投项目。
2024-12-09Mindray's Dangshan Medical Technology Industrial Park, started in April 2022, has completed partial factory竣工验收 and key equipment delivery. Its Longhua Science & Technology Industrial Park, a global manufacturing base, started construction in 2022.砀山迈瑞医疗科技产业园（2022年4月开工）部分厂房已竣工验收，关键设备交付使用；龙华科技产业园（全球制造基地）于2022年启动建设。
2025-06-09Mindray confirmed that its Dangshan base in Anhui, under construction since April 2022, will become the company's fourth-largest global manufacturing base; it has hired over 300 local employees for construction and administration.迈瑞确认，自2022年4月开工的安徽砀山基地将成为公司全球第四大制造基地；已招聘超过300名当地员工从事基建和行政工作。
2025-06-13Mindray completed the closure of its IPO-funded 'Wuhan Research Institute Project', with remaining funds of RMB 374.93 million and interest permanently transferred to working capital; all 2018 IPO special accounts (total raised RMB 5.752 billion) are now closed.迈瑞完成IPO募投项目“武汉研究院项目”结项，节余资金3.7493亿元及利息已永久补充流动资金；2018年IPO募资57.52亿元的全部专项账户已清理完毕。
2026-01-26Mindray disclosed that its new Dangshan production base has achieved full coverage of digital supply chain systems and is connected with the Nanjing base for multi-site production coordination.迈瑞披露新建砀山生产基地实现了数字供应链系统全覆盖，并与南京生产基地实现系统联通，支持多基地生产协同。
Share buybacks and insider purchases股份回购与内部增持
19 · 2024-12-24 → 2026-06-22
▾
Chairman Li Xiting and executives buy back shares and increase holdings董事长李西廷及高管回购股份并增持
2024-12-24Mindray disclosed it completed two share buyback programs (each 1 billion RMB) in 2021 and 2022, for employee stock ownership plans and share cancellation, and stated it has no new回购 plan to disclose currently.迈瑞医疗披露已于2021年和2022年完成两轮各10亿元人民币的股份回购（用于员工持股计划和注销），目前暂无新回购计划。
2025-01-07Board Secretary Li Wenmei purchased 3,000 shares at 241.01 yuan per share, totaling 723,000 yuan, increasing holdings to 22,300 shares.董事会秘书李文楣以均价241.01元增持0.30万股，金额72.30万元，持股增至2.23万股。
2025-01-13Two previous share buyback programs (each 1 billion yuan) completed; first two tranches of 2022 ESOP unlocked, third tranche pending per plan.前两轮各10亿元回购方案已实施完毕；2022年员工持股计划前两期已解锁，第三期按计划操作。
2025-03-14Mindray board secretary Li Wenmei increased her holdings by 1,900 shares on March 11, 2025, with a transaction amount of 463,300 yuan, at an average price of 243.83 yuan per share.迈瑞医疗董秘李文楣于2025年3月11日增持1900股，成交金额46.33万元，成交均价243.83元/股。
2025-04-24Mindray stated it has completed two share buyback programs of RMB 1 billion each in 2021 and 2022, for employee stock plans and share cancellation.迈瑞医疗表示已于2021年和2022年完成两轮各10亿元的股份回购，用于员工持股计划及股份注销。
2025-05-19Mindray's 2022 employee stock ownership plan third tranche (1/3 of total) failed to vest due to unmet 2024 performance targets; shares will be recovered by the plan's management committee.迈瑞医疗2022年员工持股计划第三批股份（占总份额1/3）因2024年业绩考核未达标全部不得解锁，由管理委员会收回。
2025-11-27Mindray's chairman and co-controller Li Xiting initiated a share buyback plan of RMB 200 million via centralized竞价 trading over 6 months from Nov 27, 2025. On Nov 27, he bought 152,340 shares at avg RMB 196.862/share, totaling ~RMB 29.99 million. Post-buyback, Li and concert parties control 51.48% of shares.迈瑞医疗董事长、实际控制人之一李西廷启动2亿元增持计划，自2025年11月27日起6个月内通过集中竞价增持。11月27日首次增持15.23万股，均价196.862元/股，合计约2999万元。增持后李西廷及其一致行动人合计控制51.48%股份。
2025-12-02Chairman Li Xiting made his first-ever share purchase on Nov 27, buying 152,340 shares at avg. 196.862 yuan, totaling ~29.99 million yuan, and disclosed a plan to buy up to 200 million yuan more over 6 months.董事长李西廷于11月27日首次增持，以均价196.862元买入152,340股，合计约2999万元，并披露未来6个月内合计2亿元的增持计划。
2025-12-02Senior VP Li Zaiwen followed up on Nov 28, buying 14,700 shares at avg. 203.52 yuan, worth ~2.99 million yuan.高级副总经理李在文于11月28日跟进增持，以均价203.52元买入1.47万股，金额约299万元。
2025-12-15Chairman Li Xiting completed his 200 million yuan share buyback plan ahead of schedule (Nov 27 - Dec 12), buying 1,005,381 shares (0.08% of total) at avg. ~199 yuan, with a 6-month lock-up.董事长李西廷提前完成2亿元增持计划（11月27日至12月12日），累计买入1,005,381股（占总股本0.08%），均价约199元，锁定期6个月。
2025-12-18Director and Senior VP Guo Yanmei bought 8,200 shares at avg. 193.56 yuan on Dec 17, worth 1.5872 million yuan, increasing her holdings to 13,200 shares.董事、常务副总经理郭艳美于12月17日以均价193.56元增持0.82万股，金额158.72万元，持股增至1.32万股。
2026-01-05Director and senior executive Guo Yanmei and senior executive Li Zhaoyang increased their shareholding by a total of 50,000 shares (0.0041% of total share capital) on 2025-12-31.2025年12月31日，董事高管郭艳美、高管李朝阳共增持公司股份5.0万股，占公司总股本0.0041%。
2026-03-04Mindray VP Li Chaoyang increased his shareholding by 18,000 shares on 2026-03-03, and another 5,000 shares on 2026-03-04 via竞价交易, totaling 24,500 shares in two days; cumulative增持 45,000 shares since 2024-07-30 costing about 8.41 million yuan.迈瑞医疗副总经理李朝阳于2026年3月3日增持1.8万股，3月4日再增持5000股，两日合计增持2.45万股；自2024年7月30日以来累计增持4.5万股，耗资约840.79万元。
2026-03-12Mindray chairman Li Xiting completed a share buyback plan, cumulatively increasing holdings by 1,005,381 shares for a total of 200 million yuan (including transaction fees); core management also increased holdings.迈瑞医疗董事长李西廷完成增持计划，累计增持公司股份1,005,381股，增持金额共计人民币2亿元（含交易费用）；核心管理层也增持了公司股份。
2026-03-30Mindray's board approved the cancellation of 641,963 shares held in treasury under the 2022 employee stock ownership plan due to unmet performance targets, reducing total share capital and registered capital accordingly.迈瑞医疗董事会批准注销2022年员工持股计划中因业绩考核未达标而剩余的641,963股库存股，相应减少总股本和注册资本。
2026-04-03Vice General Manager Li Zhaoyang purchased 5,000 shares via competitive bidding on April 2, 2026, costing RMB 812,200.副总经理李朝阳于2026年4月2日通过竞价交易增持5000股，耗资81.22万元。
2026-04-03CFO Zhao Yun purchased 10,000 shares via competitive bidding on April 2, 2026, costing RMB 1.6258 million.财务负责人赵云于2026年4月2日通过竞价交易增持1万股，耗资162.58万元。
2026-05-20Mindray vice general manager Li Zhaoyang increased shareholding by 10,000 shares via block trade, costing approximately RMB 1.5493 million.迈瑞医疗副总经理李朝阳通过竞价交易增持1万股，耗资约154.93万元。
2026-06-22Mindray Vice General Manager Li Chaoyang purchased 8,000 shares via竞价交易 for RMB 1.0989 million, increasing his holdings to 158,000 shares.迈瑞医疗副总经理李朝阳通过竞价交易增持8000股，耗资109.89万元，持股增至15.8万股。
Hong Kong secondary listing香港二次上市
14 · 2025-07-23 → 2026-06-25
▾
Mindray plans and refiles H-share listing on Hong Kong Stock Exchange迈瑞计划并在港交所重新提交H股上市申请
2025-07-23Mindray is considering a Hong Kong secondary listing, targeting at least $1 billion (HK$7.8 billion) in fundraising; the company responded that official information should be relied upon.迈瑞医疗正考虑在香港进行二次上市，预计募资至少10亿美元（约78亿港元）；公司回应称以官方发布信息为准。
2025-08-03Mindray is reportedly considering a secondary listing in Hong Kong, aiming to raise at least USD 1 billion (approx. HKD 7.85 billion).迈瑞医疗正考虑在港二次上市，预计筹资至少10亿美元（约78.5亿港元）。
2025-10-14Mindray announced plans to issue H-shares and list on the Main Board of the Hong Kong Stock Exchange, with issuance not exceeding 10% of total share capital (pre-over-allotment) and up to 15% over-allotment option, to fund international expansion, R&D, and working capital.迈瑞医疗宣布拟发行H股并在香港联交所主板上市，发行规模不超过总股本的10%（超额配售权行使前），并授予不超过15%的超额配售权，募集资金用于国际化布局、研发投入及补充运营资金。
2025-10-14Mindray's board approved the appointment of Ernst & Young (Hong Kong) as the special auditor for its H-share listing on the Hong Kong Stock Exchange.迈瑞医疗董事会批准聘请安永会计师事务所（安永香港）为其H股香港上市专项审计机构。
2025-10-14Mindray's board approved the revision of the Company's Articles of Association and related governance rules to comply with Hong Kong Listing Rules, effective upon H-share listing.迈瑞医疗董事会批准修订《公司章程》及相关治理制度，以符合香港上市规则，自H股上市之日起生效。
2025-10-30Mindray's 2025 first extraordinary general meeting approved all resolutions related to the H-share listing, including the issuance plan, conversion to an overseas-issuing joint-stock company, and appointment of auditors, with over 99.92% approval for special resolutions.迈瑞医疗2025年第一次临时股东大会高票通过H股上市相关全部议案，包括发行方案、转为境外募集股份有限公司及聘请审计机构等，特别决议案同意比例均超过99.92%。
2025-11-10Mindray submitted an H-share listing application to the Hong Kong Stock Exchange on Nov 10, 2025, for a main board IPO. Joint sponsors: Huatai International and JPMorgan. The draft application was published on HKEX website.迈瑞医疗于2025年11月10日向香港联交所递交H股上市申请，拟在主板挂牌上市。联席保荐人为华泰国际和摩根大通。草拟申请资料已在港交所网站刊登。
2025-11-10Mindray's H-share IPO prospectus disclosed: planned H-share issuance not exceeding 10% of post-IPO total shares, with 15% over-allotment option. Proceeds to fund globalization, R&D innovation, and working capital. The company ranked 23rd among global top medical device firms, with 6 products in global top 3 and 9 products No.1 in China by 2024 revenue.迈瑞医疗H股招股书披露：计划发行H股不超过发行后总股本10%，另设15%超额配售权。募资用于全球化、研发创新及运营资金。公司位列全球医疗器械企业第23名，6类产品全球前三，9类产品中国第一（按2024年收入计）。
2026-03-02Mindray disclosed that its H-share listing application submitted to HKEX on 2025-11-10 is still pending approvals from CSRC, SFC, and HKEX; average CSRC filing time for A-share companies in 2025 was about 148 days.迈瑞医疗披露，其于2025年11月10日向港交所提交的H股上市申请尚待中国证监会、香港证监会和港交所批准；2025年A股公司境外上市备案平均用时约148天。
2026-04-01Mindray's H-share listing is under regulatory review; proceeds will fund global R&D, sales network, and supply chain. A special cash dividend to existing shareholders is possible before the Hong Kong listing.迈瑞医疗H股上市正在监管审核中，募集资金将用于全球研发、销售网络及供应链建设，不排除在港股上市前对现有股东派发一次性特别现金股利。
2026-05-08China Securities Regulatory Commission (CSRC) issued supplementary materials requirements for Mindray's Hong Kong IPO, covering data privacy, use of proceeds for overseas investment, technology import/export compliance, overseas subsidiary regulatory procedures, and controlling shareholder share pledge.中国证监会对迈瑞医疗港股IPO出具补充材料要求，涉及数据隐私、募集资金境外投资用途、技术进出口合规性、境外子公司监管程序及控股股东股权质押等六项事项。
2026-05-10Mindray's Hong Kong IPO prospectus filed on 2025-11-10 lapsed automatically after six months without progress.迈瑞医疗于2025年11月10日递交的港股招股书因满6个月未获进展自动失效。
2026-05-11Mindray re-filed its Hong Kong IPO application with updated financial data and compliance materials; joint sponsors are Huatai International and JPMorgan.迈瑞医疗更新财务数据及合规材料后重新向港交所递交上市申请，联席保荐人为华泰国际和摩根大通。
2026-06-25Mindray CEO Liu Laiping met with Haikou city officials to discuss cooperation in drug-device R&D, smart healthcare, bonded repair, and cross-border trade under Hainan Free Trade Port.迈瑞医疗行政总裁刘来平与海口市官员会晤，探讨在海南自贸港框架下于药械研发、智慧医疗、保税维修、跨境贸易等领域合作。
